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RICE UNIVERSITY 
ABSTRACT 
The Immune System and Pathogen Co-Evolution 
by (Seyed) Pooya Hejazi 
Chairperson of the Supervisory Committee: Prof. Michael W. Deem 
Dept. of Bioengineering 
A thesis presented on the co-evolution of the immune system and pathogens. The 
generalized NK (GNK) model is used to describe the fitness landscape upon which 
the evolution proceeds. Evolution from the scale of viruses to organisms is 
considered. 
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Introduction 
The interactions of the immune system and pathogens that lead to their co-evolution 
are very broad, complicated, and at times fascinating. The motivation behind this 
work was to contribute to the framework of developing better treatments for 
pathogens in general and for vaccines in particular. In the case of vaccines, one has 
to answer the question of why standard methods of vaccine development are so 
effective with certain pathogens and fail against others. 
There are many pathogens against which we do not have effective deterrents, and 
though they many seem drastically different from each other, most of these 
pathogens have evolved along with the immune system and take advantage of built-
in characteristics of the immune system. The choice of generalized NK model to 
simulate the evolutionary landscape of immune-pathogen co-evolution has allowed 
for a central link among various specific interactions of the immune system and 
many different pathogens. Just as in statistical mechanics there is a search through 
configuration space to find regions of favorable free energy, so too in evolution 
there is a search through sequence space to find proteins, pathways, and organisms 
of high fitness. The immune system is a real-time example of evolution, as our body 
creates and modifies molecules of the immune system in response to invading 
pathogens. Many pathogens respond to this immune pressure by evolving 
themselves. We provide a full synopsis of each chapter in a compressed format in 
the paragraphs below. 
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Chapter I: The first chapter is a brief appraisal of the literature in theoretical aspects 
of the adaptive, vertebrate immune system: The immune system recognizes a myriad 
of invading pathogens and their toxic products. It does so with a finite repertoire of 
antibodies and T cell receptors. We here describe theories that quantify the dynamics 
of the immune system. We describe how the immune system recognizes antigens by 
searching the large space of receptor molecules. We consider in some detail the 
theories that quantify the immune response to influenza and dengue fever. We 
review theoretical descriptions of the complementary evolution of pathogens that 
occurs in response to immune system pressure. Methods including bioinformatics, 
molecular simulation, random energy models, and quantum field theory contribute 
to a theoretical understanding of aspects of immunity. 
Chapter II: The second chapter shall focus on the development of immune and 
pre-immune repertoire of mammalian immune system and its diversity: It has been a 
long held belief in immunology that the random combinations of the VDJ regions 
give rise to the antibody diversity of the immune system prior to any somatic 
hypermutations. Here we present clear evidence of regulation of diversity in 
development of the immune system in fetal pigs using high throughput sequencing 
of variable region of heavy chain before any transcription into proteins. The 
experiments were designed to rule out genetic and environmental factors, such as the 
loci of VDJ segments in the genome, pathogens from the surroundings, and 
placental cross-talk To our knowledge this is the first study under such conditions in 
the mammalian immune system. Fetal pigs were found to utilize less than 54% of the 
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heavy chain VDJ diversity available to them. More importantly, we found 
convergence of expression between fetal pigs both in segment identity, as well as 
over time and organ translocations. Such convergence in time and tissue type among 
different animals can only be brought about by a regulatory system that controls the 
diversity of expression during various stages of development of die immune system 
repertoire. 
Chapter III: The third chapter shall discuss the influenza pathogen and its 
interactions with the immune system: Studies of influenza virus evolution under 
controlled experimental conditions can provide a better understanding of the 
consequences of evolutionary processes with and without immunological pressure. 
Characterization of evolved strains assists in the development of predictive 
algorithms for both the selection of subtypes represented in the seasonal influenza 
vaccine and the design of novel immune refocused vaccines. To obtain data on the 
evolution of influenza in a controlled setting, naive and immunized guinea pigs were 
infected with influenza A/Wyoming/2003 (H3N2). Virus progeny from nasal wash 
samples were assessed for variation in the dominant and other epitopes by 
sequencing the hemagglutinin (HA) gene to quantify evolutionary changes. Viral 
RNA from the nasal washes from infection of naive and immune animals contained 
6% and 24.5% HA variant sequences, respectively. The effective diversity of the 
mutations from the naive animals was 88% and 78% from the immune animals that 
of theoretically possible. Definition of effective diversity here is the evenness of total 
number of mutations among all the mutant cites. Also, immunization increased the 
number of mutant sites by 20%. Moreover, the number of variants, i.e. could be 
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different amino acid mutations be it at the same cite, increased by 94%. Yet the total 
number of mutant strains increased by 407%, showing many repeated identical 
mutations. Typically one would expect these three numbers, the number of mutant 
sites, total number of variants, and total number of mutant strains, to be identical. 
Such a stark contrast of 20 and 4 fold respectively between the increase in mutation 
cites and increase in total number of mutant strains, and between increase in the 
mutations variants and the increase in the total of number of mutant strains is 
evidence of significant bias and non-randomness in the mutations, which happen to 
be at the same sites and of the same type. These results indicate that these sites and 
types of mutations that are utilized by the progeny strains in a repeated fashion are of 
significant evolutionary value over random mutations, and could be utilized to make 
predictions about sites and types of mutations for future variant strains. Analysis of 
mutations relative to antigenic epitopes indicated that adaptive immunity played a 
key role in virus evolution. HA mutations in immunized animals were associated 
with loss of glycosylation and changes in charge and hydrophobicity in and near 
residues within known epitopes. Four regions of HA-1 (75-85, 125-135, 165-170, 
225-230) contained residues of highest variability and can be identified as sites that 
are adjacent to or within known epitopes and may play as yet an unappreciated role 
in antigenic variation than previously thought. Recognition of the role of these sites 
during evolution can provide useful insight in the development of future novel 
vaccines using the immune refocusing technology. 
Chapter IV: The fourth chapter discusses the development of antibiotic resistance in 
extended spectrum resistant bacteria carrying the ^-lactamase gene: Under conditions 
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of environmental change, recombination and horizontal gene transfer tend to 
increase both modularity and rate of evolution in biology. In bacteria, the 
contribution of recombination to mosaic gene structures acquisition of antibiotic 
resistance is well known. The main evolutionary mechanism behind development of 
extended spectrum p-lactamase antibiotic resistance has long been considered to be 
accumulation of single point mutations, with recombination cited as a mechanistic 
facilitator of increased mutation rates. In this study, presence of recombination was 
detected in the evolution of antibiotic resistance in clinical bacteria carrying extended 
spectrum ^-lactamase genes by the bioinformatics methods DNASP, Reticulate, 
LDhat, START, Splits Tree, and Sites. The methods of recombination detection 
were calibrated against data from statistical mechanics simulations of evolution, 
which generated sequences under selection. Since certain strong selection pressures 
can mimic the effects of recombination, which the extended spectrum clinical 
isolates experience due to antibiotic selection at specific active sites, detection 
methods diat relied upon silent polymorphic sites to largely avoid such selection 
pressures were also used. Additionally, linear and logistic regressions were used to 
further test the reliability the results. Our findings suggest that recombination plays 
an evolutionary role in the development of antibiotic resistance by not only 
facilitating but also combining the mutations. 
Chapter V: The fifth chapter examines the human rhinoviruses (HRV) pathogen: 
HRV are the most common source of viral infections worldwide. The common cold, 
caused by many distinct strains of HRV, not only causes direct infections in humans, 
but also modulates the immune system, at times initiating or exacerbating chronic 
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respiratory conditions such as asthma and respiratory wheezing. While HRV 
infection is the most prevalent cause of viral infections, less than half of more than 
100 distinct strains have been fully sequenced , with many of those not sequenced 
having been identified for decades, and less than a tenth have their protein structures 
established. This could be in part due to almost exclusive specificity of HRV for 
human cells, and the need until recently to use human or primates as experimental 
subjects instead of small animals. Using sequence data obtained from clinical studies 
in human, we examine the mutation sites entropies in virus progeny strains to gain 
some insight as to where the epitopes of HRV are located on the viral capsid. 
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Chapter I 
THEORETICAL ASPECTS OF BIOLOGY AND IMMNUNITY 
Annu. Rev. Chem. Biomol. Eng. 2010. 1:247-76 
The Annual Review of Chemical and Biomolecular 
Engineering is online at chembioeng.annualreviews.org 
This article's doi: 10.1146/annurev-chembioeng-073009-100952 
Copyright c 2010 by Annual Reviews. 
1. Introduction 
Just as in statistical mechanics there is a search through configuration space to find 
regions of favorable free energy, so too in evolution there is a search through 
sequence space to find proteins, pathways, and organisms of high fitness. The 
immune system is a real-time example of evolution, as our body creates and modifies 
molecules of the immune system in response to invading pathogens. Many 
pathogens respond to this immune pressure by evolving themselves. The chapter is 
a brief appraisal of the literature on the theoretical aspects of the adaptive, vertebrate 
immune system. 
The immune system exhibits many of the mathematical features that make biology 
interesting (1). Finite timescales in biology bring out the importance of dynamics, 
and finite population sizes bring out the importance of randomness, correlations, 
and fluctuations. Biological information and structure are organized hierarchically, 
and modularity is a key principle that we will use in describing the immune system. 
At a deeper level, the emergence of the adaptive immune system in jawed vertebrates 
several hundred million years ago is an example of the spontaneous emergence of 
modularity, die symmetry breaking phase transition by which biology itself emerged 
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from organic chemistry several billion years ago (2, 3). Finally, the response of the 
immune system induces a complementary evolutionary dynamics in pathogens. 
In this chapter, we discuss some of the theoretical aspects of immunity. In Section 2, 
we provide an overview of the adaptive immune system, including a discussion of 
the generalized NK theory that has been developed to describe immune system 
dynamics. In Section 3, we cover traditional ordinary differential equation (ODE)-
type models of the immune system. In Section 4, we describe some of the 
bioinformatic approaches to vaccine design. We continue the discussion of vaccine 
design with a consideration of theories about the collective, population-level effects 
in Section 5. We elaborate with an explicit consideration of the dynamics of virus 
spread in Section 6. We explain the statistical mechanics of the immune response to 
influenza in Section 7, and present die statistical mechanics of the immune response 
to dengue fever in Section 8. The pamogen reacts to the immune response, and we 
describe general theories of pathogen evolution, some derived from quantum field 
dieory, in Section 9. We discuss the theories used to understand the evolution of 
influenza virus in Section 10, and describe theories for other diseases in Section 11. 
We conclude with a brief sample of dieories to explain the immune response to 
cancer in Section 12. 
2. Brief Summary of the Immune System 
Our immune system protects us against deauh by infection. There are two major 
components of the adaptive vertebrate immune system—the antibody-mediated 
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humoral response and the T-cell mediated cellular response. In this chapter, we 
discuss quantitative models of the immune system response to often highly variable 
pathogens. The variation exists either because the disease mutates at a non-negligible 
rate or because the disease exists in multiple subtype forms. 
These models can help us deduce design rules for vaccines can be deduced. The 
finite size of the immune system repertoires and the existence of immune system 
memory make the immune system response to variable viral diseases nontrivial. 
Several reviews have covered some of the interesting aspects and challenges the 
immune system poses (4-7). 
2.1 The Humoral, B Cell Immune Response 
Viruses, bacteria, and other pathogens are recognized and repelled from infecting 
our cells by antibodies, which are proteins produced by our B cells. Antibodies 
recognize patches, called antigens, on the surface of pathogenic proteins (Figure 1, 
see color insert). To recognize the many different pathogens that can attack us, we 
have a repertoire of different B cells that each produce a different antibody. The 
human immune system has on the order of 108 different B cells, and the probability 
that a given antigen will be recognized by a given antibody is approximately 1 in 105. 
The immune system uses a hierarchical strategy to search through the space of 
possible antibodies to find those that recognize antigens. There are approximately 
100 amino acids in the variable region of an antibody chain, and so there are 
12 
approximately 20100 or 10130 possible such structures. The immune system searches 
this large space with the sparse set of 108 structures available via a two step process. 
The first step is the initial creation of B cells that produce antibodies by joining 
together three different antibody fragments. Libraries of these fragments are 
available in the genome of the individual, and this diversity can create on the order of 
1011 different structures, although only 108 are present at anyone point in time. This 
assembly process is called VDJ recombination. When an individual is challenged by 
a pathogen, the B cells that produce the 1 in 105 subset of these initial antibodies that 
recognize the antigen are further optimized by a local search process. Essentially, the 
DNA that encodes these antibodies is randomly mutated, and the cells that make the 
antibodies that better recognize the antigen are expanded in concentration and 
number. This mutation and selection process is repeated for many of rounds and 
leads to modified antibodies that strongly recognize the antigens of the pathogen. 
This second, optimization process is called somatic hypermuation. 
Figure 1: Influenza virus hemagglutinin (Aichi 1968) trimer complex with a 
neutralizing antibody dimer [Protein Data Bank (PDB) accession number 1E08]. 
Although the immune system does not evolve a single, optimal antibody to 
recognize an antigen, it does evolve a subset of antibodies that better recognize the 
antigen. The number of distinct antibodies produced in high concentrations is on 
the order of a half-dozen or so. Indeed, the antibody response typically can be 
deconvolved to a response from a few specific antibodies (8). These antibodies 
typically bind to non-overlapping neutralizing epitopes on the pathogen. This set of 
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epitopes on the surface of pathogenic proteins is termed the "protective 
immunome." 
The portion of the antibody that binds the antigen, which is also the region that 
undergoes somatic hypermuation, is called the hypervariable region. The antibody 
protein structure in the hypervariable region is constrained to be loop-like, largely 
independent of sequence. Fundamental computer simulations have verified this 
aspect of antibody structure (9). Interestingly, simple molecular dynamics was 
insufficient to equilibrate these structures, and hybrid Monte Carlo with multi-
dimensional parallel tempering (10) was required. Parallel tempering simulations 
show that the hypervariable region, while constrained to be loop like, is sufficiently 
flexible to bind a wide range of antigens (9,11). 
2.1.1 The Generalized NK Model 
The dynamics of affinity maturation can be described theoretically by a search for 
increased binding constants between antibody and antigen in antibody sequence 
space. The immune system response to an antigen generates a high concentration of 
only a few memory B cells in response to an antigen from the pathogen. This small 
diversity reduces the ability of the immune system to respond to subsequent 
exposures to different but related antigens. It is this competitive process between 
memory sequences and newly formed VDJ recombined sequences that determine 
the effectiveness of a vaccine against a virus. 
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The Deem group has developed a random energy theory that describes the dynamics 
of the immune system and the interaction between influenza antigens and antibodies 
(12). This theory takes into account both the ruggedness of the interaction energy 
landscape upon which the antibodies evolve and the correlations in this landscape 
that allow VDJ recombination to produce a viable naive repertoire. The landscape is 
rugged due to the dramatic variation of the ability of antibodies to bind to an antigen 
as the antibody sequence is changed. There are many local maxima, of various 
heights, of an antibody's ability to bind antigen as the antibody sequence is changed. 
This model captures the essence of the correlated ruggedness of the interaction 
energy in the variable space, the variables being the antibody amino acid sequences 
and the identity of the disease proteins, and the correlations being mainly due to the 
physical structure of the antibodies. The model is population based, considering a 
population of B cells in an individual, a population of viruses, and a population of 
individual people. The random energy model permits study of the immune response 
at the level of individual antibodies and antigens. Absent this theory, study of the 
molecular interactions in detail would be computationally prohibitive because there 
are many influenza strains, 6.7 x 109 people on Earth, 108 antibodies per individual, 
and 104 atoms per antibody. Use of random energy theory to treat correlations in 
complicated physical systems has a long pedigree in statistical physics. 
The generalized NK (GNK) model describes the interaction between antibodies and 
antigens. Each antibody is identified by its amino acid sequence, and each antigen is 
represented by the coupling parameters. A successful immune response to an antigen 
corresponds in the theory to finding a set of amino acid sequences with low energy 
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for the coupling parameters that represent the antigen. The spin-glass form of the 
GNK model makes the energy landscape rugged. The energy landscape has a 
structure, however, which is induced by the local antibody structure (Usd), the 
secondary antibody structure (Usd-sd), and the interaction with die influenza proteins 
(Uc)(2). 
M M P 
i = l / > y = l i = \ 
Here M is the number of subdomains in the structure, P is the number of direct 
binding sites, and a; is the type of the ith subdomain. A detailed discussion of the 
parameter values, how they are derived from structural biology and immune system 
parameters, and robustness to change in parameter values is given in (21). An 
important feature of the theory is that the rugged landscape upon which the B cells 
that code for antibodies evolve is not completely random, but rather has structure. 
This structure is what allows productive VDJ recombinants to be formed. We were 
motivated to use a spin-glass, or random energy model, for the fitness landscape 
because we knew that evolution of proteins by point mutation alone is a slow 
process and hence the landscape must not be smooth. Moreover, we realized that 
the random energy model must be correlated, because proteins have secondary 
structures at an intermediate length scale between the amino acid and domain length 
scales. We used this theory to develop new 'subdomain swapping' protocols for 
protein evolution (13,14). 
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The approach is innovative because the GNK model can predict immunodominance 
and cross reactivity. The GNK model considers the full diversity of the B or T cell 
response, and this is why it can predict phenomena such as immunodominance, 
cross reactivity, and original antigenic sin (see Sections 2.1.3, 7.1, 7.3, and 8.1). 
Traditional ODE models can be fit to, but cannot predict, immunodominance, cross 
reactivity, and vaccine efficacy data. Traditional ODE models consider the immune 
dynamics within a small number of classes of immune cells, e.g. naive, activated, and 
memory, but do not consider the full diversity of the 108 B or T cells that exist 
within the human immune system. The GNK theory considers the full 108 diversity 
and for this reason is able to predict the immune dynamics and vaccine efficacy that 
result from skewing of and interactions among this diversity. 
2.1.2 Scaling Theory of the B Cell Immune Response 
A physically-motivated, scaling theory of the immune system gives us some in sight 
into the principles of immune recognition (15). Larger animals have more mass to 
protect, and so they have a larger immune system. In fact, both the diversity and the 
total number of B cells are greater in larger animals. Scaling theory suggests how 
these quantities depend on the mass, M, of an animal. 
The scaling theory starts with the observation that the lifespan, T0, of an animal 
scales with body mass as T0 ~M1/4 (15). The immune system must be sufficiently 
protective that the animal survives pathogen attack for this period of time, on 
average. The mass of the animal is composed of ~M3/4 service volumes, the volume 
17 
of tissue supplied and drained by one capillary. Each service volume is of volume 
~M1/4, and independently monitored by the immune system. The capillaries that 
supply blood flow to these service volumes are of universal size and function in all 
animals, and so the amount of blood and antigens that enter the service unit per unit 
of time is independent of M. If one assumes that the mobility of die B cells is also 
independent of M, then the time required for one B cell that is specific for one 
antigen to search each unit scales as the volume, ~M1/4. To keep the time of 
detection constant with animal size, there must be ~M1/4 copies of each B cell in 
each of the units. Thus, the total number of copies of each B cell should scale as 
~M 1 / 4 xM 3 / 4 ~M 
The second observation of scaling theory is that the total number of infections of an 
animal is proportional to the lifetime metabolic intake of the animal (15). The total 
metabolic rate of an animal scales as ~M3/4 according to Kleiber's law. The lifetime 
scales as ~M1/4, and so the lifetime metabolic intake must be ~M Thus, the number 
of infections against which the immune system must protect is c M, where c is some 
constant. The probability that an immune system with N different B cells will fail to 
recognize a specific pathogen is s = (1- V Q / V ) N ~ exp(-N V0/V) where VQ/V is the 
fraction of antigens recognized by a specific antibody. The probability that all 
lifetime infections are successfully repelled is (1- s)cM ~ exp(-ecM). This probability 
should be near unity, and so s c M « 1. Using the expression for s, we find N » 
(V/VQ) ln(c M). 
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This prediction that the number of distinct B cells scales as ~4n (c M), with ~M 
copies of each B cell, is consistent with known diversities in humans and mice (15). 
For example, humans have roughly 108 different B cells, with 105 copies of each. 
Mice, which weigh approximately 20g, roughly 3400 times smaller in mass than 
humans, have approximately 107 different B cells with 10 copies of each. At small 
enough masses, this scaling relation must break down. Using the numbers for 
human and mice, we find c = 0.12 g"1. Thus, the scaling relation surely breaks down 
for cM < l , o r M <8g. Recent estimates of the immune repertoire size in zebrafish 
suggest a B cell diversity of 5000 - 6000 (16). Zebrafish, however, with an average 
mass of 0.3 g, would not seem to be within the scaling regime. 
2.1.3 Autoimmune Disease and the Functional Role of Glassy Dynamics in 
the Immune System 
The VDJ and somatic hypermutation hierarchy has evolved to allow the immune 
system to rapidly recognize a wide variety of potential antigens. One might ask, 
however, if even more efficient evolutionary dynamics might be possible in the 
immune system, and if so why such dynamics has not evolved into wide usage. In 
fact it would be more efficient, if the immune system continued with recombination 
during the somatic hypermutation process (17, 18). In other words, antibodies that 
more strongly recognize antigens could be found with this process. It turns out, 
however, that these antibodies would bind not only their intended target, but also 
other targets (Figure 2). This off-target activity would lead to autoimmune disease. 
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It would appear, therefore, that the slow, glassy dynamics of evolution in the 
immune system serves a functional role to inhibit autoimmune disease. 
This calculation also provides us with an estimate of how many antibodies might be 
needed to cover antigen space. As will be discussed in more detail below, there is a 
natural measure of antigenic distance in sequence space, which we term/>epjtope. The 
immune system primed by exposure to an antigen appears able to recognize other, 
related antigens out to a distance of pepkopt = 0.19 (19) to 0.45 (20). Taking the larger 
number, we find that such an immune response recognizes approximately: 
N(p) = 19' x 20!/[z!x(20 -/)!] = 10"9 
of all possible antigens, where i; = 20x pepjlope (17). Thus, an immune repertoire 
with the diversity to allow the generation of 109 memory antibodies, not necessarily 
all at the same time, would be able to recognize most antigens. This upper limit 
agrees well with the 108 naiVe diversity of the human antibody immune system. 
Figure 2: Cross-reactivity of primary immune response memory antibody sequences 
for the two strategies against altered antigens (PM: point mutation only; PM + GSS: 
gene segment swapping in addition to point mutation), where K is the binding 
constant and p is the antigenic distance of the new altered antigen from the original. 
The cross reactivity ceases at a higher value (p > 0.472) for PM + GSS in 
comparison with PM alone (p >0.368). From (17). 
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2.2 The cellular, T Cell Immune Response 
Figure 3: A 3-D representation of T-cell receptor (TCR)- MHC-peptide complex 
(PDB accession number 2CKB). (a) A backbone tube diagram of die mouse TCR 
bound to the class I MHC H-2Kb molecule and peptide, constant (Q and variable 
(V) regions are shown. The peptide (P) is also shown., (b) Mouse TCR a and P 
chains binding the MHC-peptide complex: the view from above of complementary 
determining regions (CDRs). (c) Above view of surface region of the class I MHC 
H-2Kb molecule and peptide. After (21). 
The cellular immune system performs a stochastic search of T cell receptors (TCRs) 
to recognize antigenic peptide ligands that are presented by the major 
histocompatibility complex (MHC) of individual cells (Figure 3, see color insert) (20). 
Multiple identical TCRs on the cell membrane binding to the ligand activates the T 
cells, which like antibodies are constructed from modular elements, with each 
individual human having a diversity of approximately 2 xlO7 different receptors (22). 
T cells originate in bone marrow and mature in the thymus. They acquire their 
diversity through the stochastic process of VDJ recombination. During the 
development of TCRs, they undergo rounds of selection for increased avidity. Unlike 
antibodies, they do not undergo somatic hypermutation, presumably because further 
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evolution may yield TCRs with unnecessarily high affinity and cross-reactivity against 
other short peptides present in the body and cause autoimmune disease (17, 18). 
Some mature T cells proliferate and produce effector T cells, whereas others become 
memory cells. 
The important components of the T cell response are die peptide-MHQ complex 
(pMHQ and the (TCR). Typically, for CD8+ T cells, the peptide is on the order of 
nine amino acids long, and the T cell-mediated response is driven by cycles of 
concentration, expansion, and selection for better binding constants. The replication 
rate of T cells in the immune system is a function of the fitness given by the 
generalized NK model. The binding energy quantifies activation of die T cells, and 
specific lysis quantifies the rate at which infected cells are killed. The replication rate 
defines replication, and the binding energy quantifies activation. Some T cells are 
activated more than others. T cell activation depends on their stimulation by antigen, 
as well as other stimulatory factors within die immune system (Figure 4, see color 
insert). The difference in replication rate between different T cells, as it depends on 
dieir stimulation by antigen, is of interest in die theory of immunity, and this 
difference in replication rate depends on the amino acid identity of the TCR. 
Moreover, die replication rate changes when the pMHG complex to which the T 
cell binds changes. There are interactions within a subdomain of the TCR (Usd), 
between subdomains of the TCR (Usd-sd), between the TCR and die peptide 
(Upep-sd), and direct binding between die TCR and peptide (Uc), as described in 
Section 2.1.1 (23). 
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We use the GNK model to describe the interaction between the TCR and the 
pMHC, where the binding constant, K, is given by (23): 
K = e"-"u 
The ability of one T cell to recognize an infected cell, z, is obtained by: 
2^ min( 1 , 
N .,„ t" , v ' X10 
size i= 1 
The specific lysis, L, or the probability that the infected cell is lysed by the T cell, can 
be calculated using: 
zE I T 
1 + zE I T 
Figure 4: The generalized NK (GNK) model of the TCR selection dynamics where 
antigen recognition expands T cell concentration according to their level of 
stimulation by the antigen. Over 10 cell divisions the concentration can expand by 
three orders of magnitude, reducing the diversity to 0.5% in the primary response. 
When a previously infected individual with memory cells to epitope A is 
subsequently exposed to a new epitope B, the immune response shall be a 
combination of the memory response from the prior exposure to A and a naiVe 
response to B. Our theory measures the contributions of both components. The 
values of zm and zn are the memory and naive clearance probabilities, respectively, 
defined below. From (23). 
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Another general theory of the T cell response is kinetic proofreading, which seems 
to occur (24). The basic idea is that a series of binding interactions leading to 
activation can yield a non-linear amplification of the signal. Denoting the complex 
between the T cell and the pMHC as Q, a series of intermediate activated complexes 
is denoted by Q, and the final active form is denoted Q,. Each activated complex 
satisfies 
d q / d t = kq. 1-kq-k 1q, Q,+1=o 
Thus, one finds that the ratio of final activated complex to total complex is Qj / £ ; 
Q = [k/(k+k_1)]N. Thus, the amount of activated complex depends in a highly 
sensitive and non-linear way on the equilibrium constant for T cell and pMHC 
binding. In this way, ligands of different affinity may elicit qualitatively different 
signals. 
A final theory of the T cell response is serial triggering (25). The mechanism of T 
cell activation seems to require multiple interactions with the TCR, not merely a 
single, very high affinity interaction. Indeed, if the affinity is too great, for example 
owing to a low-off rate, then the TCR is unable to achieve a sufficient number of 
interactions. In this way, die T cell has evolved into a sensitive detector of small 
numbers of antigenic determinants present on infected cells. 
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2.2.1 Self-Immunity 
T cells created in the bone marrow pass through the thymus before proceeding to 
the lymph nodes and blood (26). T cells that bind no antigen in the thymus are 
eliminated. T cells mat bind antigen weakly are kept. T cells that strongly bind 
antigens from ones own proteins are eliminated because they would cause cross-
reactivity and autoimmune disorders. Thus, TCRs are enhanced in weak-binding 
amino acids. Crystal structures support this conclusion that TCR occurs via multiple, 
modest interactions. We can understand this suppression of strongly binding amino 
acids with the following physical argument (26). The interaction between the TCR 
and the jth of the M peptides in the thymus is denoted by-E(l,j), and the cutoff to 
avoid negative selection is denoted by -EN. Thus, whether the T cell will survive 
negative selection, i.e. not bind too strongly to any of the peptides, is given by p(I) = 
rii=i M 9[(EN - E(l,j)]. The average survival probability is <p(I)>= <6(EN-E(l,j)>^, 
where one has assumed that the peptide compositions are independent. Making the 
further assumption, which we know from the GNK model is not true but which 
perhaps does not greatly detract from the present argument, that the interaction 
energy between the TCR and the peptide is a linear sum of terms due to each amino 
acid on the peptide, E(l,j) = £i-iN J(U)> we reach the conclusion that £i=iN J(l,,j) <EN 
for each of the j peptides. In other words, the distribution of amino acids in the 
TCR must be such that <J(lj) > < EN/N. Thus, because the peptides in the thymus 
are typical self peptides, and the TCR must bind them only weakly, the amino acids 
in the TCR should be the weakly binding ones. 
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2.2.2 T Cell Receptor Clustering 
The TCR is bound to the surface of T cells. In some cases, the receptors aggregate 
during a recognition event, localizing the receptor, antigen, and kinases into a small 
area (27). This aggregation is now thought to regulate the degradation of the TCR 
A maximum of T cell signaling seems to occur for intermediate TCR-pMHC half 
lives. Too strong a binding does not allow serial triggering to cause activation and 
too weak a binding does not allow enough receptor binding to cause activation. 
Advances in video microscopy have revealed interactions between the T cell and 
antigen in lymph nodes (28). Three phases of T cell motion were found. The initial 
activation phase is termed phase I. Quantitative analysis showed that the duration of 
phase I, which can be minutes to hours, depends on the ratio of the TCR-pMHC 
half life to the time of the T cell - dendritic cell (DC) encounter (29). This ratio is a 
"consolidated measure of antigenic quality and type" (29). 
3. Traditional Ordinary Differential Equation Models of Immune Response 
and Viral Growth 
Traditionally, theoretical modeling of the immune system has been based on systems 
of ODEs that describe the time-dependent concentration profiles of pathogen, 
antigen, and B and T cells. A well studied case is that of HIV dynamics by the Los 
Alamos group (30). The disease has three phases: initial growth of the virus due to 
exposure and then suppression of the virus by the immune system, a long period of 
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low virus concentration in the body, and then finally growth of the virus again with a 
transition to AIDS. Mathematical modeling along with experiment revealed rather 
rapid virus and immune cell turnover during the second phase, which previously had 
been thought to be a rather quiescent phase. 
A subset of virus progeny are what is known as defective interfering (DI) particles, 
These which simply may be failed attempts at viral replication. These DI particles 
may also serve a functional role to inhibit the immune response against the viable 
virus particles. A differential equation approach was used to evaluate the effect of 
DI particles on vesicular stomatitis virus (VSV) growth (31). At low DI 
concentrations, both virus and DI particles were predicted to expand in number. At 
intermediate concentrations, both were inhibited. Finally, at high DI concentrations, 
DI growth was inhibited, but virus was propagated. 
A natural extension of ODE models is into the spatial dimension. Reaction 
diffusion models have been developed, for example, to examine the spatio-temporal 
patterns of viral infection (32). The model described VSV growth and spread in 
cells, using parameters extracted from imaging studies. 
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4. Bioinfoimatics of Vaccine Design 
4.1 Modification of Virus Growth Rates 
The explosion of bioinformatics data, coupled with a mechanistic understanding of 
viral growth dynamics and immune recognition, allows for a novel approach to 
vaccine design. For example, a model-based approach has been applied to the 
design of growth-attenuated viruses (33), which are used in some vaccines. These 
viruses generate an immune response, but grow poorly or not at all in humans and 
do not cause infection. The traditional experimental approach for creating such 
vaccine viruses has been to evolve them in foreign hosts, until they replicate poorly 
and are no longer infectious. By using molecular biology and bioinformatics, and 
predicting how genetic changes correlate with virus growth, it is now possible to 
design a growth-attenuated virus strain. A model has been developed to predict how 
a virus-infected cell will produce viral progeny. In particular, the model captures the 
details of virus entry, transcription of viral mRNA, translation of viral protein, 
replication of the viral genome, assembly of intermediates, and production and 
release of viral progeny (33). The predictions of this model were used to suggest 
genetic modifications that would lead to a growth-attenuated strain. 
In another study, the effect of gene order on virus growth was predicted and used to 
design a vaccine strain (34). Permutations of gene order for the The different 
permutations varied by 6000 times in their growth rates VSV were examined for 
their effect on growth. The different permutations varied by 6000 times in their 
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growth rates. Deletion of intergenic attenuating regions reduced the variation in 
growth rates to merely 20 times. 
4.2 Epitope Recognition 
Bioinformatics methods have also been used to identify and modulate the immune 
recognition of viruses. A Los Alamos group has extensively examined the humoral 
immune response to HIV. In one study, the B cell response to a DNA vaccine for 
HIV was examined (35). Nucleotide motifs that are common in HIV but under-
represented in highly expressed human genes were identified. It was postulated that 
these motifs were leading to die poor expression of die HIV proteins gag, pol, and 
env derived from the vaccine. In addition, an optimized consensus codon sequence 
was chosen for the gag gene. These bioinformatics-based optimizations gave a 
fivefold increase in antibody response to the gag protein derived from the vaccine. 
5. Collective Effects of Vaccine Design in a Population 
Viruses exist not just in an isolated individual, but in a population of individuals. 
Mathematical models can predict the sometimes non-intuitive effects of vaccine use 
in a population (36). A sufficiently powerful model would aid the effort to design a 
vaccine that is most effective in a population. A basic concepts in vaccine design is 
herd immunity. In die simplest model of viruses infecting people and propagating 
from infected people to other susceptible individuals, there is a percolation transition 
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as a function of the transmission probability of the virus. That is, no epidemic 
occurs below a critical transmission probability, whereas an epidemic that infects a 
significant fraction of the population occurs above the critical transmission 
probability. Under such a scenario the dynamical mean-field reaction rate equation is 
(37): 
d,pk(t) = -pk(t) + U[i-Pt(t)]&w 
where pk is the probability of a vertex with k connections to other vertices being 
infected, A is the rate at which an infection is transmitted between an infected and an 
uninfected vertex, and &(A) is the probability that any given link points to die node 
in question. At steady state, one obtains: 
kAQ (A ) 
Pk = 1 + kAQ {X ) 
Furthermore, we can obtain the epidemic threshold and the fraction of infective 
vertices, assuming a distribution that has finite degree fluctuations: 
x. = <k> 
< k2 > 
Here the numerator is the average number of connections to a vertex, and the 
denominator is the average of the square of the number of connections. When X falls 
below X.c- no epidemic occurs. Vaccines reduce this critical transmission probability, 
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Xc, because vaccinated individuals are much less likely to be infected by die virus. 
Thus, even people who are not vaccinated can benefit from the vaccine: If enough 
of the population is vaccinated and die vaccine is efficacious enough diat X <XC, the 
unvaccinated are completely protected. Decreasing the transmission rate below the 
critical value by means of vaccination so that no epidemic occurs is the essence of 
what is meant by herd immunity. 
Several non-trivial issues arise in vaccine design against viruses with natural diversity 
(36). For example, different host species may be infected by different versions or 
serotypes of a virus. How should vaccine composition be optimized if only some 
host species will be vaccinated? The bacterial disease Haemophilus influenza (Hib) 
contains a single serotype, whereas there are numerous serotypes of pneumococcal 
bacteria. Thus, the pneumococcal vaccine must be updated regularly, whereas the 
Hib need not be. A related question for pathogens with multiple serotypes is which 
serotypes to include in the vaccine. Mathematical models allow one to shed insight 
into this question. For example, it might be advisable to include only the most 
pathogenic subtypes in the vaccine and leave out the avirulent serotypes. This 
approach, similar to the sparing of pesticide application on a limited fraction of 
cultivated land, may allow the avirulent serotype to outcompete and suppress the 
more troublesome, virulent serotypes. 
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6. Epidemiology 
Viruses exist in a population of individuals and survive by propagation between 
infected individuals. We can calculate an upper limit on die viral spreading rate (38). 
Let us assume mat a single virus particle in a single bacterial cell reproduces in one 
day to make 100 viable progeny. The volume of a cell is 10"15 m3. If each of the 
progeny infects one other cell, the volume of infected cells is 100" x 10"15 m3 at the 
end of n days. This expansion process would be able to infect enough bacteria to 
populate the entire top kilometer of the surface of the earth, a volume of 5.1 x 1017 
m3, in 17 days. 
We know that typical viruses do not overtake the globe quite this rapidly (38). The 
reason is that the population infected by the virus is heterogeneous. Living matter is 
not well mixed. Microbes, fish, plants, birds, and mammals are distributed 
heterogeneously on the earth, and progeny of viruses do not have unfettered access 
to all other susceptible cells on the earth. Transmission of viruses is highly restricted 
by the local contact processes between infected and susceptible individuals. In 
addition, viruses are restricted by their biology to the hosts they can infect. That is, a 
given virus usually can only infect a subset of cells in one, or at most a few, species. 
Epidemiology is the study of virus spread in a population, and modern models take 
into account the heterogeneity of the transmission process and the selectivity of the 
virus. Mean field analysis of these models leads to classical results, but fails for 
spatially localized contact processes. Approaches such as moment closure methods 
32 
have been developed to account for correlations in the dynamics (39). High 
dimensional, detailed dynamics of an epidemic have been projected onto lower 
dimensions by projection operator methods (40). Some generic implications of 
spatial heterogeneity have been derived. For example, spatial heterogeneity of a host 
population tends to lead to greater disease persistence (41). Important order 
parameters to characterize viral spreading include how well the immune system 
recognizes related strains of a virus, the tiansmissibility of the virus, and population 
size (42). Three fixed points for viral dynamics have been described: global 
extinction, stable single-strain persistence, and multiple-strain persistence with strain 
diversity. The transmission rate of the virus and strength of cross immunity between 
strains determine the boundary between single and multiple strain persistence. 
Among the order parameters, population size and cross immunity most dramatically 
affect the dynamics. It was noted that "The most crucial feature of multi-strain 
pathogenesis is that infection by one strain induces partial immunity to future 
infections by other strains" (42). We will return to this point in Section 7.1. 
Influenza provides an example of how the host affects viral transmission and strain 
structure. Because of a world wide effort to sequence human influenza, so a great 
deal is known about the distribution of the virus and its various strains. Human 
influenza A viruses tend to travel around the world with the international air travel 
of human hosts (43). Frequent travelers accelerate the spread of epidemics (44), 
although seasonal epidemics are large enough and infect enough people that even 
average travelers are sufficient to distribute the virus globally. 
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Influenza predominates in the winter months of temperate climates. Several 
mechanisms have been suggested to explain this observation (45). The increased 
crowding that occurs with indoors activities, including school terms, during die 
winter months may lead to greater transmission. The immune system may also be 
fundamentally weaker in cold weather. For example, the antibody response seems to 
depend on melatonin and to be sensitive to vitamin D, both of which are lower 
during winter. Epidemics are most synchronized, i.e. more mean-field, in the more 
populous states of the US and during the most severe disease season, as one would 
expect from simple fluctuation versus number considerations. Although children are 
still believed to drive the spread of disease at the local levels of schools, households, 
and communities, the long-distance spread of the virus is better correlated with 
patterns of adult workflow traffic. Interestingly, epidemics in the tropics are 
correlated with rainy seasons. It also is known that the virus is more stable at lower 
temperatures. 
7. The Immune Response to Influenza 
Influenza is a viral disease that infects 5 - 15% of the population and causes a 
worldwide mortality of 250,000 - 500,000 annually. Influenza virus is categorized as 
either A or B. Influenza A is further subtyped by the hemagglutinin and 
neuraminidase serotypes, HxNy. The typical course of an influenza infection in an 
individual lasts 7 days (46). During the first 1 -2 days after exposure, the individual 
suffers no symptoms, although the virus is rapidly expanding in number in the upper 
respiratory tract and the individual is shedding virus and is infectious. Day 2 is the 
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day of maximum virus shedding, which lasts roughly until day 7. The degree of 
infectiousness is roughly proportional to viral shedding. Although fever is often 
considered a classic symptom of the flu, only 40% of A/H3N2, 36% of A/H1N1, 
and 7.5% of B cases cause fever. The H3N2 serotype is the most virulent and 
expands to higher viral concentrations, or titer, in individuals. H3N2 also typically 
causes more severe illness, higher mortality, and a greater number of hospitalization 
cases than does H1N1. Children shed influenza virus earlier and longer than do 
adults. 
There are multiple strains of each virus serotype (Figure 5, see color insert). The 
traditional method for quantifying differences between strains of influenza virus is 
known as the hemagglutination inhibition assay, which quantifies the ability of an 
antibody to competitively inhibit the binding of the hemagglutin protein of the virus 
to red blood cells. Antibodies raised against one strain of the virus typically inhibit 
other strains to lesser degree, in a way that depends on the difference between the 
strains. The lesser the inhibition, the greater the distance between the strains, and 
thus this assay forms a basis to quantify antigenic distance (47). These assays are 
typically performed in ferrets, however, and the correlation of antigenic distances 
derived from this animal model with vaccine efficacy in humans is imperfect. 
The annual influenza epidemics exhibit a strong seasonality in temperate regions 
(48). Furthermore, epidemics are often associated with rainy seasons in tropical 
regions. Moreover, there is a correlation between influenza transmission, vapor 
pressure, and virus survival. It has also been observed that transmission decreases 
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with vapor pressure in a linear way, and that virus survival increases with low levels 
of vapor pressure. Thus, it has been suggested that humidification of air in homes, 
schools, and workplaces could reduce virus transmission substantially. Recall that 
epidemics are percolation phase transitions, and so reduction of transmission 
probability below the critical value would extinguish an epidemic. 
From sequence data, it is now thought that the global migration of influenza drives 
epidemics (49). That is, the virus does not persist locally, flaring up during the 
winter. Rather, the virus seems to arrive from elsewhere. It is now thought that 
Asia, sometimes China and sometimes other countires, is the source of the annual 
epidemic strains (50). For example, it appears that Northern hemisphere strains are 
not descendants of South America or Africa strains, but rather of Asian strains. This 
continual source of strains induces a ID character in the phylogenetic tree of 
influenza strains. Modeling efforts have suggested that once an influenza epidemic 
reaches 104 - 105 cases, travel restrictions are unable to contain further spread (51). 
Figure 5: Phylogenetic tree of riAl hemagglutinin nucleotide sequences for FBN2. 
From (50). 
7.1 H3N2 Influenza Virus Vaccine Efficacy 
There is an annual vaccine for influenza that contains three components, currently 
specific strains of A/H1N1, A/FDN2, and influenza B. In 2009/2010 there was 
also a supplemental novel A/H1N1(2009) strain. 
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The immune response to an influenza vaccine and then subsequent response to a 
vinos that may be a bit different from the vaccine strain has been the subject of 
intense theoretical efforts (19, 52, 53). The immune system mainly recognizes the 
hemagglutinin protein on the surface of the influenza virus particle. On this protein 
there are five main regions, called epitopes, that antibodies recognize. It has been 
postulated that a suitable order parameter to characterize antigenic distance for 
influenza is the fraction of amino acids that differ in the dominant epitope between 
two strains (19, 53). This order parameter is: 
/epitope = (Number of amino acids that differ in the dominant epitope) 
(Number of amino acids in the dominant epitope) 
and correlates to a greater degree with vaccine efficacy in humans than do even the 
ferret animal model studies (19, 52). This order parameter is a useful new tool for 
influenza vaccine design (Figure 6). 
Figure 6: Vaccine efficacy for influenza is well represented as a function of pepkope. 
Also shown is a linear least square fit of the epidemiological data based on the pepitope 
parameter. Original antigenic sin, or negative efficacy, has been observed 26% of the 
time. From (19). 
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7.2 H1N1 Influenza Virus Vaccine Efficacy 
The other major serotype of influenza that has afflicted humans over the past few 
decades, and is the cause of some concern during the 2009/2010 season, is H1N1. 
As with H3N2, researchers desire to have a predictive correlate of vaccine efficacy 
for H1N1. To develop the pepmpe method, first the epitopes of H1N1 needed to be 
identified (54). Roughly one-third of the positions were known from antibody 
mapping experiments. Remaining positions were identified by structural mapping 
from H3N2 and identification of sites under immune selection pressure. With these 
epitopes in hand, Epitope f° r H1N1 was developed (20). This order parameter 
correlated well with H1N1 vaccine efficacy in humans, just as it did for H3N2. 
An interesting distinction between H3N2 and H1N1 is uiat the immune response to 
H1N1 appears to be stronger (20). This, for example, explains why H1N1 vaccines 
are typically more efficacious and why they extend protection to larger values of 
Apitope m a n d° H3N2 vaccines. It also appears that due to this greater immune 
pressure, H1N1 viruses evolve to a greater extent when they are dominant than do 
H3N2 viruses. 
7.3 Sequence Space Localization in the Immune Response to Influenza 
These measures of antigenic distance are based on a statistical physics description of 
the immune response to vaccine and subsequent exposure to virus (2). This theory 
is termed the GNK model. The GNK model is a spin glass, random energy theory 
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of the landscape upon which the immune system dynamics evolves. This theoretical 
description was the first to predict both a region of positive protection from the 
vaccine and a region of increased susceptibility due to a vaccine. Essentially, there is 
an intermediate antigenic distance for which the immune memory generated by the 
vaccine causes the immune response to be trapped in a local region of sequence 
space, and this suboptimal response is worse than if the vaccine had not been given. 
In vaccine design, a positive efficacy is desired. The GNK theory allows one to 
quantify the antigenic distance between the vaccine and mutant viral strains and to 
predict the expected vaccine efficacy as a function of this distance. 
8. The Immune Response to Dengue Fever 
Originally a tropical and subtropical disease, Dengue virus (DENV) is now being 
tracked and investigated in the United States as well as the rest of the world (55, 56). 
The number of infections seems to grow with the spread of the the range of 
DENV. The virus causes approximately 50 to 100 million cases on annual basis, with 
a conservatively estimated mortality of 25,000 mortalities per year (57). Despite being 
immune to the same strain after surviving a bout of the disease, individuals that are 
reinfected with a different serotype are at an elevated risk of suffering dengue 
hemorrhagic fever (DHF) as a symptom. DHF is characterized by plasma loss due to 
increased vascular permeability and is the cause for essentially all the mortalities 
sterriming from DENV (58, 59). To avoid this original antigenic sin, a DENV 
vaccine must be able to protect against all four serotypes simultaneously (60). To 
date, however, no four-component vaccine has been developed to combat all four 
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serotypes (61). Development is impeded by the need to overcome, or at least 
minimize, immunodominance and to bypass the potentially adverse effects caused by 
heterologous immunity. 
There are four serotypes of DV (62), which differ by up to 30% in amino acid 
composition. The ten DENV protein products, ordered by greatest to least 
variation, are NS2A, Q NS1, NS2B, E, NS4A, NS5, M, NS3, and NS4B (Figure 7, 
see color insert). These four serotypes frequently co-circulate in the same locality. 
As with influenza, Asia appears to provide the source population forDENV, and the 
greatest diversity of DENV is found in that region. In other words, there is frequent 
DENV migration with relatively little in situ evolution (63). Although the sequence 
data for DENV are not nearly as extensive as that for influenza, it does appear that 
there is significant fluctuation in genetic diversity of the virus, with rapid creation 
and extinction of many dengue clades. 
8.1 Immunodominance in the Immune Response to Dengue Fever 
Because DENV is comprised of four related serotypes, an ideal vaccine would 
provide the basis for a simultaneous and balanced attack against all four viral 
variants. Discovery of an effective vaccine against all four DENVs, however, has 
been hampered by the skewing of immune responses to only one or two serotypes. 
A fundamental problem with DENV is diat immunity after infection by one 
serotype of DENV protects modestly or even negatively against reinfection by other 
serotypes (56, 57, 64). Presence of original antigenic sin requires having a vaccine for 
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DENV that can induce protective immunity against all four serotypes simultaneously 
(56, 57, 65). To date, not only has no such effective vaccine been developed, but also 
it is believed that the T cell immunological response to each serotype is to a limited 
number of epitopes that are similar but distinct in each serotype (66, 67). Differences 
in the epitope sequences, in addition to simultaneous exposure to all four DENV 
serotypes can make the quality of the immune response to some of the serotypes 
poor (60, 65). Immunodominance is a severe immunological problem that DENV 
poses. 
Figure 7: DENV genome expressed as proteins and the levels of antibody and T 
cell immune response to each (blank no response, +: mild response, and +++: 
strongest response). From (57). 
Clinical trials for a four-component DENV vaccine (57, 60) show such 
immunodominance effect in which immune response is not strong against all 
serotypes. Why immunodominance occurs so dramatically in DENV has been the 
subject of much debate. Most studies suggest that CD8+ TCRs that recognize 
dominant epitopes inhibit expansion of TCRs to other epitopes, owing to resource 
competition, homeostasis, apoptosis, and reduction of viral load (66, 68, 69). 
However, the complexity of the interactions between the immune system and 
DENV has made a quantitative understanding of immunodominance challenging. 
Moreover, no four-component vaccine to date has been able to overcome this 
immunodominance. 
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8.2 Multi-Site Vaccination to Alleviate Immunodominance in Dengue Fever 
Based on our studies (23), we have suggested a novel multi-site vaccination that may 
ameliorate immunodominance for the DENV vaccine (Figure 8). By multi-site 
vaccination we mean vaccinating in different locations such that each component of 
the vaccine drains to a physiologically distinct lymph node, e.g., as used to be done 
with the rabies vaccine in the abdomen and buttocks (Figure 9). Ffence there would 
be independent evolutions of the immune response to various vaccine components 
in different individual lymph nodes until complete mixing, after which amplified T 
cells would spread more evenly through the lymphatic system and a fraction would 
be randomly chosen to be further expanded. Such independent selection evolution 
allows for a successful multisite vaccination by generating a predisposition in 
amplified T cells prior to mixing. Because vaccine components can preselect this 
predisposition, it can in turn be used toward sculpting the immune response to 
ameliorate immunodominance. Administration of two different vaccines at physically 
separated sites rather than the same site has been shown in cancer vaccines to reduce 
immunodominance (70-72). The model further suggests that vaccinating with a 
poorly recognized serotype first, followed by multi-site vaccination, is an effective 
strategy to sculpt an increased number of TCRs recognizing the subdominant 
serotypes to mitigate immunodominance. Finally, the model predicts that judicious 
choice of the subdominant epitopes may further ameliorate immunodominance. 
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Figure 8: Specific lysis ratios from the least to most dominant epitope of the four 
DENVs (1-4) under various experimental conditions. Data from (23). 
Figure 9: Representation of values for parameter mixing day to draining lymph 
nodes at different distances from the heart. T cells escaping from lymph nodes that 
are further from the heart take a longer time to systemicaUy mix. From (21). 
Three experimental studies in animals have now confirmed our hypothesis that 
multi-site vaccination may alleviate immunodominance (73-75). These studies 
investigated the diversity of a CD8 T cell response to a mixture of HIV epitopes. In 
(75), mice were immunized with a mixture of ALU and KV9 Db-restricted HIV 
epitopes. Injection to the same site resulted in a specific response to the KV9 
epitope, whereas anatomic separation between injection sites resulted in a response 
against both epitopes. Another study (74), assessed in mice whether a broad CD8 T 
cell response recognizing multiple HTV-1 types (termed "clades") could be induced 
by a multi-component vaccine. Single-clade A, B, and C vaccines generated limited 
cross-clade reactivity. Combining the three clades into one vaccine resulted in a 
reduced breadth of response owing to immunodominance. Simultaneous 
aclministration of individual clade-specific vaccines into anatomically distinct sites on 
the body alleviated immunodominance and increased the number of epitopes 
recognized by the T cell response. In the last study (73), a four-component dengue 
vaccine was examined in monkeys. A broader immune response was generated with 
multi-site vaccination than with single-site vaccination. A broader immune response 
was also generated when subdominant serotypes were aolministered in different 
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physiological locations than the dominant serotypes. These studies provide 
confirmation of our theory. 
9. General Considerations of Pathogen Evolution 
Emergence of drug resistant strains of pathogens exposes people to virulent 
infection and remains a significant problem (1). For example, A significant fraction 
of patients in hospitals are infected with common bacteria such as Staphylococcus 
aureus, Enterwood, and Pseucbrmas aeruginosa that are resistant to antibiotics. Many 
species of viruses evolve in response to immune or vaccine pressure, and influenza 
has become resistant to several common antivirals.. 
9.1 The Quasispecies Theory of Virus Evolution 
In the late 1960s and early 1970s, Crow, Kimura, and Eigen developed the 
quasispecies theory to describe viral evolution. This physical theory of evolution 
considers the replication and mutation of a population of viruses. The key results 
that emerged were that a population of viruses clusters around a defined genotype, 
which need not be the genotype with the most rapid replication rate, and mat there is 
a critical mutation rate, beyond which the virus species no longer can exist. The 
disappearance of the virus for mutation rates greater than the critical value is called 
the error catastrophe. 
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There is an analogy between this evolutionary dynamics and thermodynamics: 
Individual viral fitness is like energy, mutation rate is like temperature, and fitness of 
the viral population is like free energy. Quantum field theoretical treatments were 
able to make this analogy precise (76). For example, if the viral replication rate, f(£) 
depends on distance from a "wild-type" sequence, £, the population of viruses in the 
Crow-Kimura model optimizes the expression 
fm=i™xafO0-^ + ^[i-a i / 2}, 
where [i is the viral mutation rate and fm is the mean viral fitness in the population. 
The error catastrophe is a true phase transition, with an order that depends on the 
form of the fitness function and the alphabet size of the virus (77). The quantum 
field theory methods provide for quasispecies theory the exact phase diagram and 
population fitness values, derivable from this equation. 
Extension of quasispecies theory to multiple fitness peaks was made possible by this 
quantum field theory (78). This extension allows one to consider, for example, one 
region of sequence space with high viral fitness and a distinct region of immune or 
drug suppression. This refined model allows one to consider evolution of drug 
resistance or immune escape of the virus. 
The quantum field theory also allowed the incorporation of horizontal gene transfer 
(79) and recombination (80) into quasispecies theory. These phenomena are 
essential for large-scale evolution, and an accurate description of viral evolutionary 
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dynamics must include these processes. It was found that these processes affect the 
phase diagram and population fitness of the virus. Perhaps most significandy, 
however, these processes affect the ability of a finite population of viruses to evolve. 
The quasispecies theory in the literature leads to the interesting idea of using 
mutagens as antivirals. If the mutation rate of the virus could be driven beyond the 
critical value, then the virus would be eradicated. Some current antivirals may indeed 
operate by this mechanism. It has been shown that VSV can evolve to decrease its 
natural mutation rate, thus counteracting this treatment strategy (81). This response 
to lethal mutagenesis is a novel viral resistance mechanism. Modulation of the 
mutation rate in response to a change in environmental pressure is well supported by 
generalized NK studies of evolution (13). 
9.2 Co-evolution Theory 
The combination of the immune system and the virus population is a co-evolving 
system. The viral dynamics includes the error catastrophe phase transition as a 
function of viral mutation rate. In addition, however, there is an adaptation 
catastrophe for virus mutation rates too small to escape immune attack (82). Thus, 
viruses can only exist within a window of mutation rates. It might be expected that 
the immune system would try to make this window of viability as small as possible, 
by varying the B cell mutation rate and antibody receptor length. Optimizing these 
parameters in a physical model leads to values close to the biological ones (82). 
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9.3 The Emergence of New Strains of a Pathogen 
Considering a population of viruses at the mean field level leads one to suspect that 
each individual virus would maximize its reproductive rate, RQ. This analysis, 
however, is approximate because it ignores correlations in the virus population. If 
there are multiple strains and co-infection of these strains in individual hosts, the 
strains that persist in a population may not be the ones that maximize RQ (83). That 
is, the virus population will maximize total strain persistence, rather than the 
replication rate of any individual virus. This result is evident in quasispecies theory, 
where it is not the bare viral replication rate f(£) that is optimized, but rather the 
renormalized, population-level viral fitness, fm. 
10. Evolution of the Influenza Virus 
The influenza virus evolves to evade the immune response. This evolution occurs in 
the population of individuals, and the immune pressure on the virus arises from 
those individuals who have memory antibodies against die virus due to previous 
infection or those individuals who have been vaccinated. The antigenic variation of 
the virus disrupts the antigen-specific immune response (36). This variation arises 
from point mutation of the RNA that encodes the proteins of the virus that the 
immune system recognizes as well as recombination and reassortment of the genes 
of the virus between different strains. 
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10.1 Pressure on the Virus to Evolve 
The virus is under a number of different pressures that can lead to evolution. The 
first is pressure from the immune system. As discussed in Sections 7.1 and 7.2, the 
pressure from the antibody immune system can be quantified by the pepitope distance 
between the virus and any strains to which an individual has been previously 
exposed or immunized. This immune pressure extends to /?epitope <0.19 for H3N2 or 
/ W < 0 - 4 5 f o r H l N l . 
There are also pressures on the virus related to its ability to infect and transmit 
between individuals. For example, typical avian influenzas infect water fowl in the 
lower respiratory tract, whereas typical human influenzas infect people in the upper 
respiratory tract. Thus, when making the transition from birds to humans, the 
influenza virus must alter its binding specificity from what is known as an a 2,3-
linkage to sialic acid to an a 2,6-linkage (84). The ability of die virus to persist in a 
population also depends on its transmission rate between individuals, and so there is 
pressure on the virus to achieve a viable transmission rate. 
Finally, there are pressures on the influenza virus to survive antiviral treatment. 
There are several of antivirals against influenza, including neuraminidase inhibitors 
and adamantines. Adamantine resistance has evolved rather completely in current 
influenza strains (85). A single Ser31Asn replacement in the M2 protein is thought 
to be sufficient to cause resistance. This evolution of the M2 protein may have 
occurred only once, with that strain then spreading throughout the population, as all 
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adamantine-resistant viruses have a shared 17 amino acid replacement signature. The 
emergence of adamantine-resistant viruses also provides further support for the 
source-sink model with Asia as the source because adamantine use is limited in the 
United States and Australia, but a majority of the strains in these countries are 
resistant (86). 
Resistance to the neuraminidase inhibitors is incomplete at present. Neuraminidase 
inhibitors are 97% efficacious when given 29h after exposure to a susceptible strain 
(87). These antivirals inhibit the release of newly formed virus particles from 
infected cells, and when the inhibitor is given sufficiently early, the virus is cleared 
before a systemic infection is established. Two known mutations lead to 
neuraminidase inhibitor resistance: His274Tyr and Asn294Ser (88). 
Whereas specific amino acid mutations or pairs of mutations are often mentioned as 
necessary and sufficient for resistance or transmission modification, other 
mechanisms to achieve these changes are likely possible. For example, more than 
simply a 2,3- to a a 2,6-linkage changes are known to be responsible for human 
infection by avian viruses(84). In fact, the novel A/H1N1(2009) strain, which seems 
to be highly infectious and transmissible between humans, binds both a 2,3 and a 2,6 
receptors. 
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10.2 The Emergence of New Influenza Strains 
Occasionally a strain of influenza that had previously only infected birds or animals 
will appear in humans. Two recent examples are the H5N1 "bird flu" and the H1N1 
"swine flu." The jumping of a pathogen to a human host is called zoonosis, and 
occurs in three stages (89). The first stage is infection of humans, but no human-to-
human transmission. The H5N1 virus is currently in this stage. The second stage is 
localized transmission of the new strain among humans. The third stage is sustained 
transmission among humans which causes an epidemic. The novel A/H1N1(2009) 
is in this stage. 
There are several barriers to achieving the third stage (90). The virus must overcome 
the human immune system. Additionally, however, the virus may also need to 
undergo substantial evolution to achieve sustained transmission between humans. It 
has been said that "in the context of emergence of an influenza A virus strain via a 
host switch event, it is difficult to predict what specific polygenic changes are needed 
for mammalian adaptation" (91). In other words, zoonosis is not a predictable event 
with current theory. In the context of A/H5N1, there has been quite a bit of 
thought as to what would lead this virus to develop sustained human-to-human 
transmission (92). For example, A/H5N1 may aquire this capability from 
reassortment events with A/H1N1 or A/H3N2. Indeed, a significant fraction, up to 
25%, of patents infected with one strain of influenza are simultaneously infected 
with another strain, thus allowing for potential reassortment events (92). It is also of 
note that consensus sequencing, e.g. as carried out by Roche/454 machines, cannot 
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generally measure evolution within individual hosts. For this reason, published 
consensus sequences are skewed toward the dominant strains within isolates. 
10.3 Point Mutation 
Point mutation is a fine tuning of the virus once it lands in a new host. To evade the 
immune system, for example, the hemagglutinin protein must make a sufficiently 
large modification of />epitope so that immune system memory from prior infection or 
vaccination does not eliminate the virus. Taking the novel A/H1N1(2009) as an 
example, the distances between this virus and the A/H1N1 virus from the 2008-
2009 season, the 1976 swine flu strain, and the 1918 Spanish flu strain are />epitope = 
0.91, 0.28, and 0.38 respectively, , with a distance of 0.45 abrogating immune 
recognition. Point mutations contributing to other components of the viral fitness, 
such as transmission, are less well understood at present. For example, "molecular 
markers predictive of adaptation in humans are not currently present in 2009 
A(H1N1) viruses, suggesting that previously unrecognized molecular determinants 
could be responsible for the transmission among humans" (93). 
10.4 Reassortment, Recombination, and Horizontal Gene Transfer 
Segmental reassortment of the eight coding segments of influenza is a significant 
contributor to the evolution of novel strains of H1N1. For example, each of the 
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novel H1N1 strains in 1918,1947, and 1951 came about by reassortment (94), as did 
die strain in 2009. Multiple lineages of H3N2 co-circulate, persist, and reassort (95). 
One study found 14 hemagglutinin or neuraminidase reassortments over 7 years 
(45). Consistent with this study, it has been estimated that at least 2-3 reassortment 
events may occur among influenza A strains each year (96). The most common 
reassortment is incorporation of a novel hemagglutinin or neuraminidase segment 
into the virus. These proteins are also undergoing the most rapid point mutation 
evolution. It appears that the reassortment evolvability of these two proteins has 
been selected for because of sufficiently great immune pressure. Reassortment of 
these segments also occurs at an elevated rate in vitro, in the absence of immune 
selection, which suggests that the reassortment of these segments may be elevated 
owing to packaging effects. 
10.5 Novel Strain Detection 
The sequence data of influenza are consistent with large selection pressure (97). 
Although there are long periods of stasis of the dominant strain, this suppression of 
fluctuations is to be expected in a finite population. Even strong selection pressure, 
e.g. from the immune system, could lead to a relatively homogeneous virus 
population during one season but rather different populations in other seasons. The 
existence of this selection pressure, suppressed as it is by finite population effects, 
has not been widely recognized (98). 
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Thus, identification of new strains, before they become dominant, is a significant and 
non-trivial task. The annual influenza vaccine for the northern hemisphere is chosen 
in February for aclrninistration in October. Thus, novel strains must be identified at 
least 9 months in advance of when they will be dominant if a vaccine against them is 
to be created. As discussed in Section 7, strain classification has been based on the 
ferret hemagglutination inhibition assay, but the correlation between the ferret and 
human immune responses is imperfect. By projecting the strains in the 
multidimensional sequence space into a 2D sequence space, clusters containing 
incipient new strains can be identified months to years in advance (99). It appears 
that novel strains can be identified with clusters containing as few as ten strains. 
10.6 Detailed Simulation of Antibody Binding 
Immune memory from infection in previous years imposes a pressure on the virus to 
evolve. The pressure is due to antibodies produced in the immune system that 
chemically bind to the hemagglutinin protein on the virus surface. Vaccinated 
individuals have antibodies that bind the virus protein 102-103 times as strongly. 
When mutations that allow the virus to escape from the immune pressure occur, 
they are typically selected for. In particular, some mutations may disrupt the 
antibody/hemagglutinin binding more than others. We postulated that the free 
energy of the binding is directly correlated to the fitness of the virus (54). That is, we 
propose that the decrease in the binding constant between antibodies and the 
mutated hemagglutinin is one of the most significant driving forces of influenza 
virus evolution. We have used molecular dynamics (MD) simulation with the 
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CHARMM22 force field to calculate the Gibbs free energy AAG from which the 
change of binding constant 
K' 
—^ = exp(-AAG/RT) 
is obtained, where K'a and Ka are the binding constants of the mutated complex 
and the wild type complex, respectively. Thermodynamic integration, with an 
Einstein crystal refrence system for the endpoints, was used to calculate this free 
energy difference. 
We performed calculations on the 1968 H3N2 Aichi strain (100). We noticed that 
the 10 observed mutations had different levels of stability, and some mutations 
persisted whereas others reverted to the original residue one or two years after die 
first mutation. We found that the mutations that persisted in the human populations 
were those that most disrupted AAG. We also calculated the free energy change for a 
double mutation found in a guinea pig animal model experiment performed by our 
collaborators. This mutation significantly disrupted AAG. 
10.7 Projected Dynamics 
Coupling virus evolution within individuals to the transmission of the virus in a 
population leads to a large system of stochastic dynamics. Analytic progress is 
possible when this dynamics is projected to a lower dimension. For example, stage-
structured modeling reduces the number of variables (101). This approach is a 
projection of an agent-based approach to be discussed next. 
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10.8 Agent-Based Modeling 
Agent based modeling provides a full solution to the stochastic process of virus 
evolution in a population. Fluctuation effects are particularly significant for 
capturing effects of strain emergence and extinction (1). Deterministic modeling, in 
particular, often leads to an excessive number of strains, with a paucity of extinction 
(102). 
A full agent-based model uses pepkope distances to capture the immune pressures on 
the virus in an individual due to prior exposure or immunization (103). Each 
individual acquires an immune history specific to its exposure history. Viruses mutate 
and evolve in individuals and transmit to other individuals. Thus, the variables are 
the current infection status and immune history of each individual. Transmission 
between individuals occurs via social contact, and so the contact network within and 
between cities is a key parameter in the formulation of the dynamics. 
Figure 10: The vaccine effect on cumulative attack rate for the initial introduction of 
two strains. The multiple-component vaccine (Mc) is superior to the single-
component vaccine (Sc) for different fractions of population vaccinated (V). After 
(103). 
This detailed model offers specific predictions for the progression of an influenza 
epidemic and how vaccination may modulate the epidemic (103). The attack rate in 
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the population—the fraction of the population that becomes infected during a 
season—is of prime interest and is calculated (Figure 10). The greater the fraction of 
the population vaccinated, and the earlier the vaccine is administered, the lower the 
attack rate. In this way, herd immunity is quantified. In some cases, a multi-strain 
vaccine is warranted. For example, in the 2009/2010 season both a season and a 
novel H1N1 vaccine will be available. This detailed, agent based approach is the first 
to quantify the efficacy of a multiple strain vaccine. The interactions among vaccine 
components can be non-trivial. The reports in 2009 of potential negative 
interactions between the seasonal and the novel H1N1 components of the vaccine, 
which concerned three provinces in Canada enough to delay administration of the 
seasonal vaccine until the novel vaccine was ready, are an example [the decision was 
based on preliminary results—not yet published or reviewed—from four Canadian 
studies involving 2000 people (D. Low, personal communication)] (104). To further 
quantify the potential impact of an epidemic, the quantity Population at Risk (PaR) 
was introduced. The PaR is the maximum expected attack rate, calculated to a 90%, 
95%, or 99% confidence interval. 
11. Evolution of Other Viruses 
Antigenic variability falls into several patterns for general pathogens. These patterns 
are (105): 
1. limited variation within host and population-wide variation that is 
independent of space and time (e.g., Stivptoax&ts pmurrxraai); 
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2. limited variation within host and population-wide variation that 
depends on space and time (e.g., Neisseria rrBmng,tides); 
3. limited variation within host, limited population variation at one time, 
but rapid population variation over the time scale of years (e.g., 
influenza); 
4. significant variation in host over time and extensive and increasing 
diversity in the global population (e.g., HIV-1); 
5. limited or no antigenic variability, limited diversity in the population, 
and thus nearly complete vaccine or naturally acquired immunity (e.g., 
measles, mumps, rubella). 
A strong immune cross reactivity between strains leads to large distances between 
evolving strains. Conversely, a rapid strain turnover is promoted by higher 
transmission, weaker cross immunity, and short-lived infections. The prevalence of 
a pathogen is increased for higher transmissibility for infections with longer duration, 
or for less cross-immunity. Thus, pathogenic diversity is greater for more 
transmissible pathogens and for weaker cross immunity. A failing of simple 
epidemic models is that diversity is generated too fast. 
Antigenic diversity is a major challenge to vaccine design, as we saw in Section 7 for 
the specific case of influenza. For viruses such as HIV or hepatitis C, one wonders 
whether a vaccine can be protective in a diverse population of hosts (105). For 
influenza, one wonders whether a universal vaccine, one not requiring annual 
updates, is possible. 
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Modeling has shed light on a few features of viral emergence (84). For example, due 
to their higher mutation rates, new RNA viruses are more likely to emerge than 
DNA viruses. In addition, zoonosis is more likely from generalist than specialist 
viruses. Epistatic effects stemming from the necessity to replicate in different hosts, 
however, disallows much amino acid variation and reduces the speed with which 
zoonosis occurs. Whereas phylogenetically related species are more likely to have 
cross species transmission, similar immune systems in related species may suppress 
virus transmission in new species; detailed modeling could provide insight into this 
phenomenon. 
11.1 Evolution of the HIV Virus 
Multiple drug, highly active antiretroviral therapy (HAART) therapy for HIV has 
significantly increased the life expectancy of infected patients. The effects on HIV 
evolution, however, are less clear (106). For example, although HAART increases life 
expectancy, it also increases viral transmission. However, decreased infectiousness 
decreases the transmission. Thus, mathematical models can determine: 
1. optimal use of HAART; 
2. epidemiological consequences of HAART and behavioral changes; 
3. the course of evolution of drug resistance within an individual and within a 
population; 
4. achievable levels of coverage and effectiveness, including effective and 
efficient use of second line treatments and demographic or health care 
impacts. 
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Several features of HIV evolution have been determined. For example, there is a 
significant bottleneck as the virus transmits from one person to another. HIV 
diversity decreases 99% during transmission to new host (107). The evolution of 
HIV also slows down as CD4+ T cells decline, presumably because the immune 
pressure is reduced (108). 
A quasispecies model for HIV evolution demonstrated the emergence of mutants 
(109). The time scale for a substantial diversity to evolve was 1-2 years. As the 
mutants emerge, the diversity taxes the capacity of the immune system to respond, 
owing to immunodominance. This mechanism was the first to explain, in a single 
model, the three phases of HIV (Figure 11). Moreover, this mechanism suggests a 
forward-looking vaccine strategy. If a subset of the mutants that are likely to evolve 
in 1-2 years are vaccinated against during week 14 using the multisite protocol of 
Section 8.2, then immunodominance is alleviated, and the immune system is 
predicted to eradicate the HIV. 
Figure 11: HIV-1 infection time course. Circles represent the clinical data and the 
solid line is generated by the model. From (109). 
The effects of recombination on HIV also have been investigated (110). At 
moderate population sizes, recombination increased diversity and mean fitness. At 
larger population sizes, recombination increased fitness but decreased diversity. For 
small population sizes, we generally expect that recombination may increase fitness 
owing to a reduction of Midler's ratchet effect (111). For larger population sizes, 
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recombination may increase or decrease fitness depending on the sign of epistasis 
(79,112). 
11.2 Evolution of the Hepatitis C Virus 
The evolution of hepatitis C has been quantified after orthotopic liver 
transplantation (113). Under conditions of mild fibrosis, genetic distance and non-
synonymous mutations in the viral quasispecies increased. Under conditions of 
severe fibrosis, the opposite happened. The interpretation is that under mild disease, 
there is less pressure on the virus, and a more complex quasispecies can emerge. 
Conversely, under severe disease, there is substantial pressure on the virus, and a 
more localized and less complex quasispecies emerges. 
11.3 Evolution of the Dengue Virus 
DENV has only recently entered the human population, and the virus continues to 
evolve in the human host. Homologous recombination has been observed in the 
Flamindae family to which DENV belongs (114). Recombination within each of the 
DENV strains has been observed (95). Conclusive proof of recombination between 
strains has now been obtained from a patient infected with DEN-1 and DEN-2 as 
well as DEN-1,2 recombinants (115). These results illustrate the general importance 
of recombination to viral evolution. 
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12. Cancer 
The immune system controls pre-cancerous cells on a daily basis. Theoretical 
discussion of cancer and the immune system focuses on cancers of the immune 
system, immune control of cancer, and potential vaccination strategies. 
12.1 The Mutations Leading to Cancer 
As an example of detailed modeling, a simulation study of human follicular 
lymphoma B cells has been carried out (116). A model of the germinal center was 
constructed, many of detailed parameters were identified. The focus of the study 
was to identify mutations leading to cancerous cells. 
12.2 Immunodominance 
The refractory nature of cancer to many standard therapies has led to substantial 
efforts to achieve immune control. Various effects, including tolerance and 
immunodominance, however, have limited the ability of the immune system and 
vaccines to control cancer. These effects occur because cancer is effectively a multi-
strain disease, with multiple cancer-associated or cancer-specific epitopes. 
Immunodominance is one general mechanism by which cancer cells may escape, 
either by mutation of the dominant epitope or by loss of the MHC class I allele that 
expresses the dominant epitope. Cross-presentation of the lost dominant epitope on 
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surrounding cells often sustains the futile immune response. Indeed, cancerous cells 
of many types are exceptionally adept at evading the immune response. 
12.3 Multi-Site Vaccination 
One suggestion for breaking the effectively monovalent response to a multivalent 
cancer vaccine is to inject the different vaccine strains in different physical regions of 
the patient, thereby breaking the immunodominance hierarchy (117). These 
experiments are well explained by the GNK theory of T cell response to multiple 
antigens (21,118)(Figure 12). Because cancerous cells often express multiple, similar 
epitopes, this theory could explain a significant fraction of the immunobiological 
responses to cancer. 
Figure 12: Specific lysis for a two-component vaccine with two completely different 
cancer epitopes, (a) Single site injection. (B) Dual site injection with each epitope in 
the vaccine draining to a different lymph node. Ffere E/T is the effector to target 
ratio and is a measure of the concentration of T cells. From (21). 
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Chapter II 
EVIDENCE OF REGULATION OF DIVERSITY IN THE 
DEVELOPMENT OF THE IMMUNE SYSTEM REPERTOIRE IN A 
MAMMALIAN MODEL 
Introduction: 
Despite the volume of research and effort that has gone into characterizing the 
immune system, the diversity of an individual's antibody repertoire and the factors 
governing it are still not completely resolved [1-3]. It has been a lingering question as 
to what would be the diversity of an individuals immune and pre-immune system, 
were it not influenced by extrinsic environmental factors. Traditionally, due to large 
number of immune cells and lack of ability to thoroughly sample the immune system 
in its entirety, prior studies have been extrapolating from much smaller samples [4]. 
Furthermore, characterization of the immune system was held back by lack of 
proper gene mapping [5] and not being able to rule out selection and bias [6-9]. 
There have been very few studies characterizing in a rigorous fashion the realized 
diversity of the complete immune and pre-immune repertoire in comparison with 
what is potentially available to the organism [10,11]. In addition to needed 
technological advances to over come the need for extrapolation, lack of discernment 
between intrinsic and extrinsic factors complicated the establishment of 
developmental diversity of pre-immune system's antibody repertoire free from any 
environmental biasing. A common assumption is that combinatorial arrangements of 
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the VDJ that give rise to the pre-immune repertoire are random, and if there is any 
bias it is due to segment order in gene [12,13]. 
In the higher order organisms, the recognition process that discerns between self and 
non-self is by means of T-cell receptors and B-cell antibodies in the adaptive 
immune system. The strengths of the adaptive immune recognition such as its 
specificity are a by product of its diversity. Even for the smallest vertebrates species 
the number of antibody producing B-cells are upwards of 105 (upwards of 1010 in 
humans) [14]. There are two mechanisms involved in giving rise to this diversity: 
combinatorial arrangements of the VDJ regions of gene encoding the antibodies 
along with junctional diversity, and somatic hypermutation in the variable regions of 
the heavy and light chains in the antibody. Since there is no somatic hypermutation 
contributing to the pre-immune system diversity, it has been presumed that the 
diversity of variable region amplified through combinatorics and junctional diversity 
are responsible for specific recognition of the broad range of patiiogens. 
Recent studies conducted in the field have raised many interesting questions. The 
number of variable heavy chain genes in many species, once estimated on the order 
of 1000, has dropped by orders of magnitude to roughly 100 genes in human and 
mammals in general and to approximately 30 genes all belonging to the ancestral 
VH3 genes in swine [15-18]. Such prominent role for the ancestral VH3 family is 
observed in many mammals other than swine but not in humans. Human VH genes 
come from 7 different VH gene families in contrast to swine. However, there are 
only about 37 functional VH genes in humans which is not far apart from that of 
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swine. In [10] it was shown that non-randomness of VDJ recombination in pathogen 
free environments in zebra fish. Such non-randomness has been previously 
documented in the literature where there is disproportionate usage of certain VH 
genes in rabbits, mice, and humans [6-9,19-21]. Nevertheless it has always been 
attributed to extrinsic or unobserved intrinsic biasing factors such as placental cross-
talk [22-24]. 
Since there is no placental cross-talk of immunoglobulin in pigs, in contrast to 
studies in other mammals [25,26], the fetal swine model with less than 30 VH genes, 
2 functional DH genes, and a single function JH gene, can be used to shed more 
light on the lingering questions about the immune system diversity, specifically the 
pre-immune repertoire. In this study we examined VH usage in VDJ rearrangement 
in yolk sac at various stages of gestation. The results of these studies showed a strong 
convergence in time and tissue type among different animals that can only be 
brought about by a regulatory system that controls the diversity of expression in the 
immune system repertoire. 
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Materials and Methods: 
DNA and RNA extraction. Fetal swine tissue samples were obtained from 
euthanizing pathogen-free pregnant pigs to obtain the yolk sac at 20 days of 
gestation (DG), the liver at 30 and 50 DG, the spleen, ileal Peyers patch and bone 
marrow at 95 DG. Upon collection, the solid organs were placed directly into liquid 
nitrogen to freeze. For processing, the solid tissues were pulverized frozen and their 
DNA and RNA extracted from separate aliquots of each sample using DNAZol and 
TriZol, repectively (Invitrogen, Carlsbad, CA). Bone marrow was recovered form 
long bones after removal of cartilaginous ends and portions were extruded with 
saline and processed in DNAZol and TriZol. RNA samples were treated for 20 
min at 37°C with ribonuclease-free Dnase and then reverse transcribed to cDNA 
using Superscript III enzyme (Stratagene) and oligo(dT) primer. 
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Amplification of gene fragments. VDJ sequences from each DNA and cDNA 
sample were amplified by PCR using a primer set comprised of FR1 and anti-sense 
JH. The product was tested for size on an agarose gels and was then cloned into 
pCR4 TOPO (Invitrogen). DNA samples from insert-containing clones were bound 
to replicate nylon membrane using a 96-well dot-blot manifold. 
Identification of gene fragments. Nylon membranes containing the cloned VDJ 
fragments were hybridized with VH gene-specific probes for sequences in CDR1 
and CDR2 of the major genes as well as a pan-specific probe to FR2 (Table 1) 
[5,18]. Clones that hybridized to FR2 but not CDR1 and CDR2 sequences were 
designated as representing unknown gene fragments (UNK) and were identified by 
DNA sequence analysis. Sequences were compared to all 30 previously 
characterized porcine VH genes [18] to determine if they: (a) were seldom-used 
germline VH genes, (b) represented new VH genes or (c) were mutated versions of 
known VH genes that failed to hybridize because of their mutations. A portion of 
the clones could be assigned to known gene fragments based on the DNA sequence 
data. Those which could not be assigned were designated UNK and include VDJ 
clones that contain either seldom seen VH genes or major VH genes that have been 
somatically mutated [18]. 
Probe sequences. Table 1 lists the sequences of the oligonucleotides used as 
probes to identify gene fragments. Columns labeled CDR1 and QDR2, list the 
vernacular designation used in the laboratory for the porcine VH genes. When the 
locus is fully mapped, the nomenclature will be changed to VH1, VH2 etc by 
numbering from 3' to 5'. There are also two VHA genes in the genome. The more 
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upstream VHA is designated as VHA* and requires a special probe (Table 1, VHA*) 
that binds in the FR3 region for identification. 
Table 1 
Probe sequences used to identify common porcine VH genes 
VH 
Gene 
VHA 
VHB 
VHG 
VHE 
VHF 
VHC 
VHZ 
VHY 
VHA* 
CDR1 
A 
B 
G 
E 
F 
C 
E 
C 
A 
CDR2 
A 
B 
E 
E 
F 
C 
C 
A 
A 
Pan 
Probe sequence for CDR1 
3FR1 
CAGT 
TTCAGT 
TCAGT 
GT 
GT 
TCAGT 
GT 
CDR'l 
AGTACCTACATTAAC 
GACAACGCTTTCAGC 
AGTTATAGCATGGAGC 
AGTTATGCAGTGAGC 
AGTTATGGCGTAGGC 
AGTTATGAAATCAGC 
AGTTATGCAGTGAGC 
AGTTATGAAATCAGC 
51=2 
T 
TGG 
T 
TGG 
TG 
T 
TG 
AGAGACAACTCCCAGAACAGG 
CGCCAGGCTCCAGGGAAG 
Probe sequence for CDR2 
3F2 
TGGCA 
TGGCA 
CDR2 
GCTATTAGTACTAGT 
GCCATTGCTAGTAGTGAC 
GGTATTGATAGTGGTAGTTA 
GGTATTGATAGTGGTAGTTA 
TCTATTGGTAGTGGTA 
GGTATTTATAGTAGTGGTAG 
GGTATTTATAGTAGTGGTAG 
GCTATTAGTACTAGT 
FR3 
FR2 
Results and Discussion: 
We found that less than 54% of the available diversity in the variable region of IgG 
genes was taken advantage of by the individual animals, which establishes an upper 
threshold of 54% for the diversity of VDJ combinations. The results repeated 
themselves among various individuals within each data group, as well as among 
various groups providing data from different tissues at different developmental 
timelines. High correlation among immune cells being sampled from different tissue 
types rules out any influence that could have been observed due to the different 
tissues hosting the immune repertoire during different developmental stages. Since 
using DNA and cDNA prior to any transcription ruled out selection influence and 
bias, the only other factor to be ruled out was random replication bias. We ruled out 
any such bias by simulating the random spread of the data and obtaining their 
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correlation values. The correlation measures were performed on the distribution of 
usage of various IgG heavy chain variable region genes from individual animals or 
averages of individuals, whose samples were obtained at the same gestation time and 
from the same tissue type. As it was observed in our plot, there is a very distinct 
contrast between the correlation distribution characteristic of the results, and those 
simulated under the random replication bias assumption. The simulations were 
obtained from correlations of randomized usages of various gene segments in each 
individual animal, as though the uneven usage of gene segments were due to random 
replication bias. Consequently, there was only one type of bias left: systematic 
replication bias, also known as a regulatory system. Incidentally under a regulatory 
system, there is an expectation that regulation of the immune repertoire would show 
greater similarity in related individuals (members of the same family) - as it was 
observed in the data, where related individuals had about double the fraction of 
correlations with a value of 0.9 or above (greater than 60%, as compared to non-
related individual that had slightly over 30%). All these observations lead to our 
belief that the bias in the usage of certain genes in the variable region of the IgG 
encoding sequence could only have come from a regularity system controlling the 
expression of the genes. 
The observed results were quite striking to us. Not only the usages of IgG variable 
segments were not evenly spread or random, but also they did not correspond to the 
loci order of the gene segments. Though mentioned before, it is important to 
emphasize that the results relied on sequencing DNA and cDNA only prior to any 
transcription into proteins. This fact along with samples being obtained at various 
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early developmental stages of the immune system repertoire ensured that there was 
no selection involved. It has been a long held belief that without selection biasing die 
immune system repertoire, one would obtain a uniform sampling of the available 
diversity [12]. Our results imply a biased distribution of VDJ usage in the pre-
immune and immune system repertoire. More striking was that the immune system 
diversity seemed to increase initially, subsequently have a slight decrease, and finally 
stabilize during the gestation period. This was of particular interest to us because it 
showed that the diversity, though being able to increase to higher levels, is held at 
mid-level in pathogen free environment, which would keep die immune system in a 
standby mode to preserve resources. It has been reported in other recent 
publications that introduction of pathogens and particularly parasites to the new 
bom piglets kept in germ free isolators drastically increases the diversity of the 
immune system in these animals [27-29]. Such reports along with our observations 
emphasize that in a pathogen free environment the immune system repertoire is on a 
standby mode and ready to expand upon encounter of pathogenic signals. 
An additional source of diversity that may not be apparent from the genome would 
be junctional diversity [11]. Nevertheless, it has been shown that junctional diversity 
does not reach its theoretical potentials due to lack of independent amino acid 
substitutions that follow the maximum entropy models and follow Zipf's law due to 
correlations between amino acids [11]. 
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Fig. 2: Summary of IgG heavy chain variable region usage with different sampling 
methods, from various tissues, and at different stages of gestation. 
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Fig. 3: Effective diversity is the Shannon's entropy measure of diversity in IgG heavy 
chain variable region. The average diversity is the mean value of effective diversities 
at different gestation time points. 
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Fig. 4: Correlations among various data sets obtained from different tissue types and 
at various gestation periods. The simulations recreated the scenario where various 
gene segments were utilized in a random but an uneven fashion tliat could come 
about due to random replication bias. 
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Fig. 5: The correlations of data sets separated based on whether they had the same 
type of DNA sampled as data source (DNA or cDNA). The difference observed 
between the two data sets could be attributed to mutations that are generated by 
junctional diversity. 
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Correlation of Immune Repertiore in Related Piglets 
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Fig.6: Correlation of samples from related animals (siblings) sampled at the same 
gestation time and from the same tissue type 
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Chapter III 
EVOLUTION OF H3N2 INFLUENZA VIRUS IN A GUINEA PIG MODEL 
Unpublished Paper to be submitted to PLOS Pathogens under the following 
authors: Jinxue Long, Ruth V. Bushnell, John K. Tobin, Keyao Pan, Pooya Ffejazi, 
Michael W. Deem, Peter Nara and Greg Tobin 
Introduction 
Influenza is responsible for 250,000 to 500,000 global deaths annually and is 
considered one of the most important respiratory infections of humans [1,2,3]. In 
the past ten years, FDN2 has dominated in prevalence of infection and disease over 
H1N1, H1N2, and influenza B [4,5]. In the United States alone, approximately 5-
20% of the population contracts influenza illnesses leading to about 240,000 
hospitalizations and 40,000 deaths with the majority due to H3N2 [4,5]. In 
addition to morbidity and mortality, influenza causes an annual economic impact 
in the range of $80B in this country alone [5]. Although vaccination is one of 
the most important preventative methods, the current vaccine design is far from 
perfect. Due to the antigenic evolution of the virus and strain-specific immune 
responses of the host, the vaccine requires reformulation every year or two to 
offer significant protection against circulating strains not represented in the 
vaccine. In the 2007-08 seasons, for example, the vaccine was composed of 
viruses antigenically similar to A/Solomon Islands (HI), A/Wisconsin (H3) and 
B/Malaysia (Victoria). According to the results of antigenic surveillance done by 
CDC, 91% of the H1N1 viruses circulating in 2007-8 were similar to the vaccine 
strain, but only 29% of the H3N2 strains were characterized as A/Wisconsin-like 
virus. The vaccine was not a good match against circulating strains in 2007-8 
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causing larger than normal numbers morbidity or mortality predominantly due 
to a Brisbane/2007 - like virus. In an effort to match the newly emerged 
dominant virus strain, the Brisbane/2007 was then chosen to be the H3N2 
component for the 2008-9 and 2009-2010 Northern Hemisphere vaccines. Due 
to the uncertainty in the composition of future evolved strains, there are no 
guarantees that the subtype selected for a vaccine will be a close enough match 
against emerging strains. Thus, improvements in predictive capabilities could 
lead to more effective vaccines. 
The majority of the predictive data is derived from sequence analysis of virus 
isolated from humans and is therefore confounded by uncertainties in immune 
pressure caused by prior infections or immunizations. Thus, it appears essential 
to grasp more in-depth understandings of influenza evolution in more 
controlled experimental and immune settings so as to augment the predictive 
power of those tasked with choosing the composition of seasonal vaccine 
strains. Furthermore, novel technologies, such as immune refocusing, have 
succeeded in preclinical studies of being able of engineering antigens that induce 
enhanced cross-reactive immunity [6]. Identification of the most highly variable 
sites along with a better understanding of the nature of the variation can assist 
those applying the immune refocusing technology to the development of novel 
vaccines that are more protective against influenza. To gain a better 
understanding of how we can protect ourselves from future circulating strains of 
influenza, we studied the evolution of the Hemagglutinin (HA) protein in an 
infectable animal model, the guinea pig [7]. The data can be used to increase our 
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abilities to predict future circulating strains and, thereby, improve the selection of 
components of seasonal vaccines that use classical technologies. In addition, the 
results can help guide the design of engineered vaccines that are under development 
with an immune refocusing technology. 
Influenza viruses have negative-strand segmented genomes that are replicated by a 
viral polymerase that has a high error rate [8,9]. The viral polymerase subunits PB1, 
PB2, PA, and NP form complexes that replicate the viral RNA strands with error 
rates in the range of 10"4 to 105 misincorporations per nucleotide and per round of 
copying [9], 
Although the majority of variants produced by the high mutation rate are expected 
to possess reduced viability, the availability of a multitude of variants facilitates rapid 
evolution and changes in amino acids located in key epitopes foster escape from 
immune pressure. Misincorporations by the replicase have been thought to occur 
randomly throughout the genome and supply the pool of variants from which 
evolutionarily f it strains develop. Therefore, highly variant domains are likely signs of 
immunological selection. Several animal models have been used to study influenza 
infection and immunity. Although mouse, rat, and ferret models dominate the recent 
literature [7,10,11,12,13], publications from Lowen et al have advanced the guinea 
pig as a relevant model of human influenza virus infection and transmission [7]. 
Guinea pigs are susceptible to infection by unadapted human influenza virus strains 
and can transmit the virus to cage mates via aerosol [7]. The infection is largely 
centered in the upper respiratory tract and produces little outward sign of disease. In 
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the present study, virus progeny recovered from nasal washes were examined for HA 
sequence variations. The data show a non-random propensity for mutations to be 
selected for in the major antigenic sites. The present study examines the variations 
in the H3-HA that occur in both naive and immune animals for the dual purposes of 
assessing the model for recapitulation of virus evolution in humans and identifying 
evolutionary trends which can be used for prediction of future strains and 
subsequent design of novel vaccine candidates. 
Results 
Immunization and infection of Guinea pigs 
Guinea pigs were infected with influenza A/Wyoming/03/2003 prior to or after 
immunization with homologous purified HA ectodomain protein as described in 
Materials and Methods. Theories on the mechanism by which antigenic drift occurs 
in vivo are based largely on studies of the HA sequence of natural variants and of 
mutants that escape in iztm selection by anti-HA antibodies possessing virus 
neutralizing activities [14]. Numerous reports have indicated that the HA protein 
can mediate immunity from infection or disease and suggests that the HA protein is 
a leading subunit vaccine candidate. Thus, anti-HA antibody serum titers were 
followed to assess the immune status of the animals and to quantify immunological 
pressure against the HA glycoprotein. Antigen-binding titers were measured by 
ELISA against commercially produced HA (Protein Sciences, Inc.) and antiviral 
activities were assessed by both hemagglutinin inhibition (HI) and virus 
neutralization (VN) assays. Figure 1 demonstrates during the course of the 
immunization phase for Group 2 animals, ELISA titers rose to 1:100,000, HI to 1: 
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2564, and VN titers to 1:160. Sera from guinea pigs in the unimmunized, naive 
group (Group 1) did not increase in titer from a baseline value of 1:10 for all three 
assays. After 25 weeks, the guinea pigs were inoculated intranasally with 104 plaque 
forming units (PFU) of virus stock Wy-B4 produced from a plaque-purified and 
sequenced isolate of the reassorted virus, A/Wyoming/03 X PR8 XI6 IB. The titers 
showed a slight increase after inoculation with virus (week 25 to 27). 
25 27 
Weeks Post Immunization 
Figl. Immunological analysis of Guinea pig serum pools. Animals in Group 1 were 
inoculated with a mock preparation of antigen (open symbols) and then infected with 
homologous influenza A/Wyoming/03/2003. Animals in Group 2 were immunized with 
recombinant HA compounded in Incomplete and Complete Freund's adjuvant (solid 
symbols) prior to infection. Serum pools were assayed for antigen binding antibodies by 
ELISA against commercially prepared HA glycoprotein (diamond). Antiviral activities were 
measured by both hemagglutinin inhibition (square) and virus neutralization (triangle) assays. 
Arrows underneath graph indicate dates of inoculation. Immunized guinea pigs were 
challenged with influenza virus on Week 25. 
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HA sequence data from progeny virus 
The hemagglutinin (HA) glycoprotein mediates virus-cell interactions and is the 
antigenicalry dominant surface protein. The HAO protein encoding by the HA gene 
can be cleaved into HA1 and HA2 subunits. HAlcontains five defined epitopes 
involved in immunity and the mutations occurring in HA1 play a key role in virus 
escape from host immune pressure. A fragment (nt. 1-1,100) of the influenza RNA 
segment 4 encoding the HA1 subunit and all of the recognized HA epitopes was 
sequenced for the evolutionary study. 
Nasal washes collected 3 days post-infection (p.i.) were titered on MDCK cell 
monolayers to determine virus concentration. Viral RNA was purified directly from 
nasal washes, reverse transcribed, and used to produce molecular clones of the HA 
gene fragment for sequencing. 514 independently derived plasmid clones from naive 
animals and 210 independently derived plasmid clones from immunized animals 
were sequenced and compared to the original sequence of the Wy-B4 HA gene. 
Table 1 contains a summary of the sequence data. Mean virus titers in nasal washes 
of immunized animals were reduced approximately 10-fold in comparison to titers 
from naive guinea pigs (103 vs 104 pfu/mL). 6% of the plasmid clones sequenced 
from naive and 24.3% of the clones from immunized animals contained at least one 
mutation in the HA-1 subunit. 
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Analysis of HA variants showed that of the mutations found in naive animals, 40.9% 
did not affect amino acid changes (synonymous) while 59.1% caused at an amino 
acid substitution or deletion (non-synonymous). Conversely, mutations from 
Table 1. Sequence analysis of progeny virus from influenza infection of guinea pigs 
Animal Immune 
group status 
Group 1 Naive 
Group 2 immunized 
Statistical significance 
Nasal titers 
(pfu/ml) 
104 
103 
Sequenced 
HA-1 genes 
514 
210 
HA variant 
strains 
31(6.0%) 
51(24.3%) 
PO.01 
Synonymous 
mutations 
27(40.9%) 
94(59.9%) 
PO.01 
Non -synonymous 
mutations 
39(59.1%) 
63(40.1%) 
PO.01 
AA mutation rate 
per site per 
replication 
23 x 10-4 
9.0 x 10" 
PO.01 
immune guinea pigs included 59.9 % synonymous and 40.1% non-synonymous 
changes. Interestingly, the average number of mutations per variant found in naiVe 
animals was 2.1 compared to 3.1 RNA mutations per variant strain in immunized 
animals. The amino acid mutation rate was calculated using the total number of 
non-synonymous mutations observed per amino acid residue. The HA-1 mutation 
rates in naive and immune animals were 2.3 x 10"4 and 9.0 x 10"4 residues mutated per 
amino acid. 
Analysis of mutations for changes in charge and hydrophobicity 
Analysis of evolution of influenza H3N2 HA sequences indicates that changes in 
charge or hydrophobicity properties of the substituted amino acids in epitopes may 
be a major driver of antigenic escape. Therefore, the physical properties of the 
mutations observed in progeny virus were analyzed to determine whether such 
correlations can be found in the variants observed in the progeny virus from guinea 
pig infections and, if so, whether the correlations reflect immune status. 
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Examination of mutations across the entire HA.-1 regions showed that a slightly 
higher percentage of the variants from immunized animals involved charge changes 
compared to virus progeny from naive animals (Table 2, 55.6% vs. 48.7%). 
Interestingly, a higher percentage of variants from naive animals had changes in the 
hydrophobicity state as compared to variants from immunized guinea pigs (33.3% 
vs. 11.1%). 
Table 2. Analysis of Amino Acids in H A Variants 
Animal 
Group 
1 
2 
Immune 
Status 
Naive 
Immunized 
Total 
Variants 
39 
63 
Charge 
Changes 
19 (48.7%) 
35 (55.6%) 
Hydrophobicity 
Changes 
13 (33.3%) 
7(11.1%) 
X2 Test results: For charge changes, X2 = 0.45 <X2(o.o5), so, p>0.05, that means no difference between 
48.7% and 55.6%. For hydrophobicity changes, X2 = 7.55 > X o^.oi), so, p<0.01, that means the 
difference between 33.3% and 11.1% was significant. Variants here are referring to non-synonymous 
mutations types previously shown in Table 1. 
Frequency of mutations by position 
"With the aim of identifying "hot spots" of variation, the position of die mutations in 
the variants were tabulated by groups of 5 amino acids and graphed (Figure 2). The 
mutations were not evenly scattered across the HA gene in a random partem. In the 
naive group, the distribution of variants in the virus progeny contained 18 sites with 
one variant, 6 sites with two, one site widi four representative and approximately 327 
(92.9%) sites without variants. The distribution of variants in the progeny from 
immunized animals showed that 12 sites with one variant, 12 sites with two, two sites 
each with either three, four, or six, and 323 (91.5%) sites without variants. The 
Graphs in Figure 2 suggest that there were four "hot spots" with 4 or more 
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mutations that arose in the progeny virus from immunized animals. The region 
from 75-80 region had mutations Q75R, C76R, D77G and D77N; 125-130 had two 
at N126Dand four at G129E; 165-170 had one N165G, one N165S, two T167A, 
two P169L; and region 225-230 had one I226V, one R228D and two R229D (See 
also supplemental tables SI and S2 for complete list of variants). The regions of the 
highest frequency of variations (hot spots) were localized on crystallographic 
structures of the HA ectodomain using the related structure from H3N2 strain X31 
(Figure 3, adapted from 2VIKpdb, [15J. In Figure 3, epitopes are colorized and the 
hot spots of variation shown as balls for progeny virus from naive (left panel) and 
immunized guinea pigs (right panel). The figure shows that the majority of the hot 
spots are on the surface of the FIA molecule and in epitope regions. 
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Fig. 2. FEstogram of influenza mutation frequency by FIA amino acid residue. Bars 
show number of variant mutations at each amino acid observed in variants isolated from 
nasal washes of influenza virus infected guinea pigs. Panel A: variants from naive guinea 
pigs, Panel B: variants from FIA-immunized animals. Stars above bars are indicative of 
mutations that occurred within epitopes. 
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Figure 3. Location of most frequently occurring variants on 3D structure. Amino acids in 
the epitopes of the ribbon diagram of the HA protein from the related H3N2 strain X31 
was colorized such that Epitope A = Yellow, B = Red, C = Blue, D = Green, and E = 
Pink. Amino acid residues with the highest frequency of variation are shown as balls. 
Panel A shows mutations from naive guinea pigs, and Panel B from immunized animals. 
Association of mutations with epitopes 
A growing body of published data from the analysis of human viruses indicates that 
the process of influenza evolution is not random and that the majority of selected 
variability logically occurs in the epitopes. The effect of immunological pressure on 
the relative ratios of mutations accumulated in infected guinea pigs within and 
outside the five defined epitopes was examined (Figure 4). The location of the five 
major epitopes of the HA glycoprotein has been determined [16,17]. Variants 
isolated from immunized animals had a higher percentage of mutations within the 
defined epitopes as compared to naive guinea pigs (38.5% vs. 63.5%). In addition, 
the types of amino acid changes found in the variants were also different in progeny 
virus sampled from naive and immunized animals. Overall, the fraction of 
mutations that altered the charge of the residue was 42% and 65.7% in naive and 
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immunized guinea pigs respectively. Furthermore, hydrophobicity was affected by 
38.5% and 71.4% of die mutations, in naive and immunized animals. 
• outside known epitopes D B w i t h i n k n o w n eP't0Pes D outside known epitopes 
NaTve Immunized Naive Immunized Naive Immunized 
Fig. 4. FEstogram of influenza mutations by HA amino acid residue. Bars show 
the number of mutations at each amino acid observed in variants isolated from 
nasal washes of influenza virus infected guinea pigs by sets of five residues as 
numbered. 
Analysis of mutants for changes in glycosylation 
Changes in glycosylation are associated with biological properties such as the folding 
and assembly of the trimeric FIA macromolecule, recognition of cell receptors, and 
evasion of host immunity. The number of glycosylation residues in circulating FDN2 
influenza virus isolates has increased with time from seven glycosylations in the 1968 
Aichi strain to eleven in the 2003 Wyoming strain. Table 3 shows the number of 
changes to variants that affected the glycosylation status of the FIA protein with the 
identification of the site of the mutation. Of the variants isolated from naive guinea 
pigs, one each lost and gained a glycosylation site. In contrast, five variants from 
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immunized animals lost and none gained a glycosylation site. It is interesting to note 
that glycosylation sites at 248, 128, and 135 glycosylation sites are used in the 
Wyoming strain, but not its predecessors Aichi or X31. In Figure 5, the sites of 
glycosylation change found in the progeny variants from immunized animals are 
identified in black and with arrows. The majority of the glycosylation changes are 
seen on the surface of the HA molecule and in epitopes. 
Table 3. Analysis of amino acid substitutions in HA variants 
Animal groups 
Group 1 
Group 2 
Immune status 
Naive 
immunized 
Loss of glycosylation 
1 (T248P) 
5 (N165S, N165G, T167A, T167A, T135A) 
Gain of glycosylation 
1 (A128T) 
B A128T 
% * % fy 
0 
Fig 5. Analysis of Glycosylations. Panel A shows residues of wild type 
A/Wypoming/03/2003. Panel B shows the addition of a glycosylation in purple 
(A128T) and the loss of a glycosylation in cyan (T248P) in the Naive Guinea Pig Group. 
Panel C shows the loss of glycosylations in cyan (T135A, N165S, N165G, T167A) in the 
Immunized Guinea Pig Group. Epitopes A, B, C, D, E were colorized in yellow, red, 
blue, green and pink, respectively. Figure drawn using PyMOL from 2VIRpdb [15] 
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3. Discussion 
To propagate over time in the population of host targets, influenza viruses must 
escape from the immune pressure by antigenic variation. The high mutation rate of 
RNA viruses provides a ready supply of mutations, some of which may have 
replicative advantages in the face of host immunity [18,19]. Analysis of naturally 
occurring variants isolated from infected humans and other species has identified 
"hot spots" of mutation that are hypothesized to define amino acid residues 
associated with antigenic epitopes [18,20,21,22]. The most variable of the residues 
are predicted to reside within the dominant epitopes and these epitopes, for the most 
part, have been confirmed by immunological studies. Due to the complexity of 
characterizing the evolution of influenza virus through infection of human hosts, 
there is great value in studying experimental infections in animal models [23]. In the 
current study, we surveyed progeny virus directly from guinea pigs infected with 
influenza virus by cloning multiple HA genes into plasmid vectors for subsequent 
sequencing without selection of replicative-competent strains through cell culture 
passage. Rather than characterizing the most common sequence at each residue by 
bulk sequencing of mixed templates, we were able to sample individual progeny to 
uncover specific variants. 
As expected, infection of HA-immunized guinea pigs resulted in the selection of a 
higher percentage of progeny variant strains containing variations in the HA protein 
sequences as compared to unimmunized animals (24.3% vs. 6.0%, Table 1). Of the 
396 residues of the HA-1 subunit analyzed during these studies, 265 amino acids, or 
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67%, are outside and 131 residues, or 33%, are inside epitopes. 61.5% of the 
mutations characterized from the nasal washes of naiVe animals were located in 
amino acid residues outside previously defined epitopes. Thus, in the absence of 
immunization pressure, the location of the variations numerically resembled a 
random distribution, if one takes into consideration that epitope residues constitute 
about 33% of the HA protein. In contrast, 63.5% of the mutations found in 
immunized animals were within epitopes; their frequency was approximately twice 
the rate expected (33%) for a random distribution. The effective diversity of the 
mutations from the naive animals was 88% and 78% from the immune animals that 
of theoretically possible. Definition of effective diversity here is the evenness of total 
number of mutations among all the mutant cites. Also, immunization increased the 
number of mutant sites by 20%. Moreover, the number of variants, i.e. could be 
different amino acid mutations be it at the same cite, increased by 94%. Yet the total 
number of mutant strains increased by 407%, showing many repeated identical 
mutations. Typically one would expect these three numbers, die number of mutant 
sites, total number of variants, and total number of mutant strains, to be identical. 
Such a stark contrast of 20 and 4 fold respectively between the increase in mutation 
cites and increase in total number of mutant strains, and between increase in die 
mutations variants and the increase in the total of number of mutant strains is 
evidence of significant bias and non-randomness in the mutations, which happen to 
be at die same sites and of the same type. These results indicate that these sites and 
types of mutations that are utilized by the progeny strains in a repeated fashion are of 
significant evolutionary value over random mutations, and could be utilized to make 
predictions about sites and types of mutations for future variant strains. 
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In addition to an analysis of the frequency and antigenic location of mutations, the 
physical properties of the amino acid substitutions were analyzed. Amino acids that 
change local electrostatic charge or hydrophobicity can have major effects on the 
recognition of epitopes by existing antibodies. Mutations that change these two 
properties can facilitate evolutionary escape and the formation of new strains of 
virus. In naive animals, approximately 42% of amino acid substitutions that resulted 
in a change in electrostatic charge were in epitopes while 65.7% of the charge 
changes in progeny virus from immunized guinea pigs were in epitopes. Similarly, 
37.5% of the mutations changing the hydrophobic nature of the residue were in 
epitopes in naive animals, and 71.4% were in the epitopes of immunized guinea pigs 
(Figure 2). These results conformed nicely to recent analyses of sequences from 
human clinical isolates of H3N2 during its evolution from 1968 [24]. We can 
numerically present these observations by defining modularity as the ratio between 
the mutations within the epitopes to those outside of the epitopes. For the naive 
guinea pigs we obtain modularity values of 0.63, 0.72, and 0.63 for all the mutations, 
mutations resulting in a change in charge, and mutations resulting in a change in 
hyrophobicity respectively. For immunized guinea pigs, however, the values obtained 
shall be 1.74,1.92, and 2.50. Hence immunization pressures increased the modularity 
of mutations observed. 
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The HA has accumulated glycosylations during the evolution of H3N2. Over the 
past 40 years, the number of glycosylation signals has increased from 7 (Aichi/68) to 
13 (Brisbane/2007) and appears to be one method by which a virus can mask its 
epitopes from immune surveillance [25,26]. In addition, some studies have 
associated increasing glycosylations with reduced virulence [26,27] while others 
associated the loss of glycosylations with exposure of new receptor binding sites or 
new decoy epitopes [28]. Inskter et al (1993) reported the role of glycosylation in the 
control of host range and suggest that oligosaccharides on the tip of the HA are 
important to the survival of HI viruses in humans but not in ducks or swine [29]. In 
the guinea pig study, one of the strains from the naiVe group gained a glycosylation 
and one lost a glycosylation (Table 3). In contrast, five of the strains from the 
immunized group lost glycosylation sites. Glycosylations were lost at one site each in 
the A , B, and D epitopes (T135, N165, and T167, respectively). Although the 
reasons for and consequences of changes to glycosylation density during evolution in 
humans remains unclear, it appears that the reduction in glycosylations in the major 
epitopes facilitated escape from immune pressure. 
Multiple strategies have been employed to characterize immunodominant epitopes 
in viruses [9] (Caporale). 
According to the analysis of mutation frequency, there were 4 hot mutation regions 
found in our study (Fig. 2). During viral infection, the immune system appears to be 
induced to react against those immunodominant epitopes which have variable 
domains. Therefore viruses can easy escape from those kinds of capture of 
antibodies. The Immune Refocusing Technology (IRT) represents an alternative 
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approach to the development of broadly protective vaccines [6,30,31]. Tobin et al. 
had dampened several immunodominant epitopes of the influenza hemagglutinin 
glycoprotein (HA) and those immunodominant epitoeps had been shown were 
responsible to engineering a more protective vaccine candidate [6]. The hot mutation 
regions and die lost glycosylations found in our study here can be thought as 
potential refocusing site for the development of more protective vaccine. 
This result is not similar to Rambaut et al. study published in Nature [1]. They found 
that the majority of virus evolution occurred in the bird phase and not in the human 
phase. They thought that the pressure from previously infected human or 
immunized human is not a driving force in evolution. Without any antibody to drive 
viral evolution, the mutations observed in the bird hosts are presumed to be 
generated by RNA polymerase at random [9,32]. 
Our results, however, indicated that mutations in H3N2 influenza virus do arise in 
the human phase, and more importantly these mutations do not seem to be random. 
This consistent with the results of Earl et al, that considers evolvability as a 
selectable trait [33]. 
4. Conclusion 
Mutation of H3N2 virus in both na'iVe and immune animal are not a random event. 
HA specific immunity plays a key role in H3N2 virus evolution. Immunity can drive 
mutations accumulating in epitopes. And those mutations driven by immunity are 
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frequently associated with charge, hydrophobicity, and lost glycosylations. Mutations 
observed in this evolutionary study can be chosen for vaccine refocusing. 
Materials and Methods 
Cells and viruses 
MDCK cells were used for virus propagation and titration, and were maintained in 
DMEM supplemented with 7% fetal bovine serum (FBS). A sample of Wyoming/03 
X PR8 X161B virus was obtained from the Centers for Disease Control and 
Prevention (CDC). The stock is a biological re-assortment of A/Wyoming/03/2003 
(WYM) and A/Puerto Rico/8/1934 (PR8) and was prepared for the development of 
vaccine preparations by double infection of embryonated hens' eggs following 
antibody selection methods [34]. Sequence analysis of multiple plaques from the 
CDC stock demonstrated mat the material was heterogenous in HA gene sequence. 
In order to prepare a homogeneous virus for infection of guinea pigs, several parallel 
plaque-purified isolates were propagated, sequenced, and titered. The isolate used in 
die current study, Wy-B4, is a plaque-purified isolate from Wyoming/03 X PR8 
XI6 IB and carries an HA gene segment identical to the GenBank sequence 
(accession number AAT08000). 
Plaque assays 
Plaque assays were used for purification of virus isolates and quantitation of virus 
propagated both in litm and in the guinea pig. Briefly, 6-well plates were seeded at 
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50% confluence with MDCK cells. The following day, serial dilutions of influenza 
vinos were applied in 1-mL volumes for 1 hour. The monolayers were washed with 
PBS and overlain with a solution of 0.8% agarose in EMEM supplemented with 
3.5% FBS and 0.1% neutral red. Clear plaques were visible against the stained cells 
after 3-4 days incubation at 37°C The Wy-B4 isolate was purified from a well-
separated plaque and propagated on fresh cultures of MDCK. Virus stocks were 
titered in MDCK cells prior to use in animals. 
Guinea pig infection and nasal wash collection 
All of the animal work was performed at BioCon, Inc. (Rockville, MD) under 
AAALAC guidelines and I-ACUG- and ACURO-approved animal study protocol 
documents. Lightly anesthetized guinea pigs, naive or immunized, were inoculated 
intranasally with approximately 104 plaque forming units (PFTJ) of the Wy-B4 isolate 
in 0.3 mL volumes of sterile saline. Virus progeny were sampled by nasal irrigation 
of anesthetized guinea pigs using 0.5 mL PBS supplemented with 100 ug/mL 
penicillin, 100 ug/mL streptomycin and 0.3% bovine serum albumin [7]. Nasal 
washes were clarified of debris by centrifugation at 1,600 xg for 10 min and stored at 
-80°C prior to analysis. Where noted, guinea pigs were re-infected after a 6-week 
recovery period using the same dose and route. 
Guinea pig Immunizations 
Guinea pigs were immunized with recombinant HA ectodomain protein derived 
from the Wyoming/03/2003 virus. Briefly, the HA gene from the Wyoming virus 
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was truncated at the transmembrane domain and cloned into the insect cell 
expression vector, pMT-BiP (Invitrogen). Induction of stably transfected S2 
drosophila cells led to the soluble expression of ectodomain proteins that appear to 
assemble into trimeric structures by small angle X-ray scatter (SAXS analysis, data 
not shown). The recombinant protein was purified by sequential His-tag selection 
on metal activated sepharose, lentil lectin agarose, and DE-53 anion exchange resins. 
A mock preparation of antigen was prepared by the same manner using empty pMT-
BIP vector. Harlan Sprague guinea pigs, 6-8 weeks of age, were obtained (Harlan-
Spraque-Dowley, Inc.) and divided into two groups. Group 1 was given the mock 
antigen and served as a negative control for the experiment. Group 2 was given the 
HA recombinant ecto domain protein. The purified protein was compounded with 
Complete Freund's Adjuvant for initial immunizations and Incomplete Freund's 
Adjuvant for boosts at weeks 3, 5, and 10. Serum samples were taken periodically 
throughout the study for serological analysis. 
ELISA ANALYSIS OF GUINEA PIG SERA 
Immune responses were monitored by ELISA method. Briefly, Nunc Maxisorb flat-
bottom 96-well plates were coated overnight with full-length A/Wyoming/03/2003 
HA protein (Protein Science Corporation) at a concentration of 1.5 micrograms in 
0.1 mL of PBS per well. The plates were washed in PBS containing 0.1% Tween-20 
(PBS-T), then the blocking of the plates was done with 0.2mL/well of 10% nonfat 
dried milk in PBS for 2 h at 37°G Serum samples were serially diluted in 1% milk 
solution and 100 microliter aliquots were tested for binding to antigen in triplicate. 
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Plates were incubated for lh at 37° Q after which the plates were washed again using 
PBS-T. The plates were then probed with a peroxidase-conjugated goat anti-guinea 
pig total IgG antibody (Kirkegaard & Perry Laboratories, Inc., Gaithersburg, MD, 
KPL, 1:1000) for lh. Plates were again washed with PBS-T. Bound conjugates were 
quantitated by the addition of tetramethylbenzidine (TMB) substrate (KPL) for 
90sec, immediately followed by an equal volume of 0.1N sulfuric acid. Plates were 
read at 450 nm. The triplicate well values were used to calculate a mean average, and 
plate backgrounds were subtracted using readings from wells coated with antigen, 
but only detected with secondary antibody. ELISA extinction titers were calculated 
as the maximum serum dilutions that resulted in a signal that exceeded a value that 
was three times plate background (approximately 0.15 OD units). Mean values with 
error bars equal to one standard deviation of the triplicate were graphed as a 
function of time over the course of the study (will have to check on this). 
Virus Micioneutralization (VN) 
Detection of serum neutralizing antibodies was determined by a standard method 
[35], with a few modifications. Briefly, in a 96-well plate, two-fold dilutions (10 \d 
volume) of RDE-treated sera were prepared over a concentration range of 1:20-
1:2560 in assay diluent (1% bovine serum albumen in PBS containing penicillin and 
streptomycin). The plate was incubated with A/Wyoming virus (100 TQD50) for 2 
hrs at 37°G MDCK cells (3 x 104) were added and incubated 18 hrs at 37°Q 5% 
C0 2 . The cells were fixed with 80% acetone, blocked with assay diluent containing 
1% Tween-20, and probed for nucleoprotein (NP) with mouse anti-influenza 
antibodies (1:4000 final concentration of 1:1 MAB8258 and MAB8257, Millipore, 
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Billerica, MA). After extensive washing, goat anti-mouse IgG HRP (1:2000, Jackson 
Labs, West Grove, PA) was added for 1 hr at RT followed by color development by 
quantification using tetramethylbenzidine (R&D System, Minneapolis, MN). 
Absorbance was read at 450 run. 
Hemagglutination Inhibition Assay (HI) 
A standard HA-I assay was performed in blinded fashion to assess antiviral 
antibodies [36]. Prior to assay, serum samples were treated with Receptor Destroying 
Enzyme (RDE, Denka Seiken CO LTD., Tokyo, Japan) overnight at 37°C followed 
by heat inactivation for 1 hour at 56°G Two-fold dilutions of serum samples were 
mixed with A/Wyoming/03/2003 virus (at a concentration of 4 hemagglutination 
units per well) and incubated for 15 min at room temperature. 0.05mL of a 0.5% 
suspension of chicken red blood cells was added and hemagglutination was assessed 
after 1 h, as described. 
Sequences analysis 
Viral RNAs were extracted from nasal wash and tissue culture samples using the 
RNA Easy Kit (Qiagen). cDNAs were synthesized using Superscript reverse 
transcriptase (Invitrogen) and the following positive strand primer: 5'-
ATGAAGACTATCATTGCTTTAAG-3'. HA cDNA fragments were amplified by 
PCR using the above oligonucleotide with the negative strand primer. 5'-
CGCGATTGGGCCAAATATGCG3' and a maximum number of 18 cycles. Pfu 
polymerase (Stratagene) with proofreading activity was used to minimize mutations 
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introduced in the PCR amplification process. The 1056-nt fragment of gene segment 
4 containing the HA-1 coding region for was cloned into the TOPO TA vector 
(Invitrogen) and independent colonies were selected for DNA sequencing. DNA 
sequences of the HA1 fragments were compared to the original sequence of the 
Wyoming/03/2003 HA1 gene (accession number AAT08000). 
Data analysis. 
The Pearson Chi-squared statistical analysis was used to test datasets for randomness 
and assess whether two sets are statistically different. The formula used for the test 
is: 
x
 = 1=1 ^ 
where n = number of samples in set, A = the probability (p) assigned to the null 
hypothesis diat there is no difference between the two sets of data. A confidence 
level of 95%, p <0.05, was used to test for significance. 
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Table SI: List of nonsynonymous mutations observed in progeny strains from naive Guinea pigs 
Strain 
1 
1 
1 
2 
3 
4 
4 
5 
6 
7 
7 
8 
9 
Variant 
V130D 
A191H 
S193T 
C52R 
L151S 
K264R 
K140R 
V112G 
Q132H 
Q132H 
N126Y 
C14R 
A128T 
Epitope 
A 
O * 
B 
O 
O 
O 
A 
O 
A 
A 
A 
O 
B 
Strain 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
21 
Variant 
L154M 
G 4 9 D 
G181A 
I260T 
LI 64V 
Q 4 4 H 
A39V 
H184P 
L316S 
L71S 
D271G 
L384S 
V20A 
Epitope 
O 
O 
O 
E 
O 
C 
O 
O 
O 
O 
O 
O 
O 
Strain 
22 
23 
23 
24 
25 
26 
27 
27 
28 
28 
29 
30 
31 
Variant 
K173E 
G342S 
N424D 
T248P 
G132D 
Q327K 
H56Y 
F146S 
I25V 
E123G 
K276Q 
G50R 
Q211K 
Epitope 
D 
O 
O 
D 
A 
O 
O 
A 
O 
O 
c 
c 
o 
* Variants outside of the five epitopes are designated O 
Table S2: List of nonsynonymous 
Strain 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
Variant 
VI121 
Q197R 
Q211K 
D79G 
G129E 
N165S 
0 6 R 
Q211K 
T167A 
I58V 
E41G 
D188N 
T117A 
S45G 
Y195H 
T167A 
G50E 
L194P 
G129E 
G129E 
N152D 
Epitope 
O 
B 
O 
O 
B 
B 
O 
O 
D 
O 
O 
B 
D 
C 
O 
B 
C 
B 
B 
B 
A 
mutations observed in progeny strains 
Strain 
21 
22 
23 
24 
24 
24 
24 
25 
26 
27 
28 
29 
30 
31 
32 
32 
32 
33 
33 
33 
34 
Variant 
N152D 
G129E 
N125D 
C52R 
K92E 
V182A 
R228G 
D53V 
E62K 
P74L 
T65A 
P74L 
I58T 
E123K 
L118P, 
R229G 
G240E 
D190G 
R142K 
I252V 
Y161H 
Epkope 
A 
B 
O 
O 
E 
D 
D 
C 
E 
O 
O 
O 
O 
O 
O 
D 
D 
B 
A 
O 
O 
from immunized guinea ] 
Strain 
35 
36 
36 
37 
38 
39 
40 
41 
41 
42 
43 
44 
45 
45 
46 
47 
48 
49 
50 
51 
52 
Variant 
N126D 
T135A 
K145R 
K259E 
N250D 
D77N 
Q75R 
E172G 
S189G 
P169L 
S209G 
N171S 
I226V 
R229G 
P169L 
V43I 
K92R 
A163V 
R299G 
D173G 
E165G 
DlgS 
Epitope 
A 
A 
A 
O 
O 
o 
E 
D 
B 
O 
D 
D 
D 
D 
O 
O 
E 
B 
C 
D 
B 
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Chapter I V 
Evidence for Recombination Contributing to the Evolution of 
Extended Spectrum (3-Lactamases (ESBLs) in Clinical Isolates 
Introduction 
The world has witnessed a sharp increase in resistant strains of bacteria. [1] Even 
though there are guidelines now in place for administering antibiotics to prevent 
over prescription, many patients in order to reassure themselves prefer antibiotic 
treatment as opposed to no treatment [1]. The guidelines may also reduce immediate 
financial incentives of drug developing companies by restricting the use of antibiotics 
in general and the use new antibiotics for first-line therapy in particular. Resistant 
bacteria are now a significant problem confronting the global public health. More 
worrying are the predictions that this problem is only to grow due to under-funded 
research for discovery of novel and effective antibiotics [1]. We are now at a point 
where there are no treatments for certain kinds of infections. Factors limiting the 
introduction of new antibiotics include the high cost of development, significant 
market competition, and demographical changes within the United States [1]. 
Among the most frequently used antibiotics are the (3-lactam drugs, which include 
the penicillin and cephalosporin families. The most common method of resistance to 
this type of antibiotic is by bacteria carrying a gene that encodes for [^ -lactamase, 
thereby producing an enzyme that hydrolyzes antibiotic by cleaving its amide bond 
[2]. This gene can be on a plasmid, which means it can be acquired even from distant 
strains of bacteria through transformation, transduction, and conjugation. The two 
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(3-lactamase families TEM and SHV are among the most common in Grant-negative 
bacteria. We looked at TEM and SHV variants of [3- lactamase genes from clinical 
bacterial strains. For these studies all TEM and SHV sequences in Genbank were 
obtained, and then only those that were clinically observed as specified by the Lahey 
Website were used for the analysis. It is presumed that the original gene has been 
picked up from soil bacteria [3]. The TEM and SHV families of the resistance gene 
were both originally found in E. ooli and Klebsiella pneummae. However, now they are 
in nearly all bacterial species of Entercbacteriamie. 
TEM is one of the most prevalent plasmid-mediated resistance enzymes in Gram-
negative bacteria (a class A p-lactamase) [2]. A single gene consisting of 861 base 
pairs encodes it. The entire population that is available via Lahey website is resistant 
to penicillin and cephalosporin antibiotics. The extended-spectrum antibiotics 
developed in the 1980s, in addition to die inhibitors that were used to block the f$-
lactamase enzyme, are degraded by the later generations of TEM making bacteria 
containing TEM highly virulent. 
SHV had been considered a chromosomally encoded species-specific enzyme in 
Klebsiella pneumoniae [4,5]. As another class A ^-lactamase, SHV is 60% identical to 
TEM in the nucleotide sequence, 67% in the protein sequence, and 81% identical in 
the surface residues. It also has a gene mat is 861 base pairs long and resistant to 
Cefotaxime mostly. Nevertheless it has shown to be able to cause resistance to other 
(3- lactams such as Ceftazedime [4]. 
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Due to genetic proximity of (3- lactamase genes in bacteria with varying degrees of 
resistance to antibiotics, it has been a long held belief that transition from one level 
of resistance to another level comes about by accumulation of single point 
mutations. More recently, it was shown that bacteria under severe stress for survival 
have a mechanism to increase diversity through increased mutation rate also known 
as SOS response. This mechanism leads to an increase in diversity, which in turn 
makes the population more likely to include the new resistant strains that shall be 
selected by the pressures of the new environment. Even though it has been 
established that recombination plays a role in the mechanisms that bring about the 
higher rates of mutation in stressed bacteria [6,7], other (non-mechanistic) 
contributions of recombination have not been investigated as thoroughly. To our 
knowledge mere has not been a recombination characterization of clinical strains 
carrying the [3-lactamase resistant genes. 
Our previous publications had showed the power of recombination to accelerate 
evolution [8-12]. In scenarios where the protein used by the organism is traveling a 
short distance in the fitness landscape to overcome the selection pressures, it is 
presumed that accumulation of single point mutations due to DNA replication can 
happen fast enough that recombination may not be needed play any significant role 
in the evolutionary development. However, there are several features that might 
suggest recombination plays a role: 
1. The [3-lactamase resistance has been transferred into infectious bacteria 
from soil strains by transformation, transduction, and conjugation. 
Multiple conjugative plasmids carrying various (3 -lactamase genes are 
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commonly observed in clinical studies, and each of these plasmids can 
have multiple copy numbers. More importantly certain antibiotics can 
hasten this process and speed up resistance evolution through 
recombination [13]. 
2. Mutations in 8 sites give rise to about 30 different varieties of TEM out 
of 256 theoretically possible combinations and mutations in 5 sites give 
rise to about 15 different varieties of SHV ^-lactamase genes out 32 
theoretically possible combinations. If the evolution of the [3-lactamase 
genes were by independent random mutations and did not involve 
recombination, one would expect independent evolutionary trajectories, 
without any siginificant overlap of mutations among various strains. 
3. Recombination can bring together advantageous mutation in various 
combinations in ways that evolving into local minima can be avoided. 
Additionally, gradual accumulation of mutations should not create 
exhaustive combinations of them as is observed for some of these 
clinical strains. 
4. Gene rearrangements, including amplification, are the other evolutionary 
process in bacteria, and can be recombination based. 
5. Certain strains of bacteria, which can carry multiple p-lactamase genes on 
conjugative plasmids and any of these plasmids can have multiple copy 
numbers, are naturally transforming in the wild and allow for free 
recombination. In these strains not only recombination changes the 
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alleles by up to 10 times more than mutations, but also individual 
nucleotides are up to 80 times more likely to change by recombination 
than mutation [14]. 
The above factors suggest recombination could play an evolutionary role, in addition 
to the mechanistic role of giving rise to mutations in stressed bacteria [6]. It turned 
out that strong selection on the active site residues of resistance leads to evolutionary 
characteristics that mimic recombination and makes it hard to distinguish the 
evolutionary paths taken. This posed the biggest challenge to establish an 
evolutionary role for recombination distinct from mutation in the development of 
extended-spectrum antibiotic resistance. Nevertheless, there are genetic signatures 
that can determine whether multiple mutations have come together via 
recombination or gradual accumulation. In this study we try to shed light on this 
issue in order to untangle the evolutionary contributions of mutation and 
recombination. 
In our previous publications, we have elaborated on the power of recombination to 
speed up evolution in biology [8-12]. Since being able to evolve at a faster pace than 
the competition is of essence in die survival of a population, the ability to increase 
the pace of evolution through recombination is vitally important. Nevertheless, 
establishing presence of recombination, in clinical isolates that have evolved in the 
wild without any of the controls that are available in a lab setting using sequence data 
only, is a challenging task. In addition to recurrent mutation mimicking 
recombination signatures and creating false positive detections, lack of any ancestral 
117 
tree for the (^ -lactamase genes families and the gene being only 861 nucleotides long 
significantly confound the problem at hand. 
Results 
For this study we employed the best available software programs of various 
designs (DNASP, Reticulate, LDhat, START, Splits Tree, and PhylPro) to detect 
recombination in the evolution of antibiotic resistance in clinical bacteria carrying 
extended spectrum ^-lactamase gene. For better understanding of the results, the 
software programs used for recombination detection were calibrated against data 
from statistical mechanics simulations of evolution and able to generate genetic 
sequences with known characteristics. Since certain strong selection pressures can 
mimic the effects of recombination Lahely Website's extended spectrum clinical 
isolates that had been under intense antibiotic selection at active sites, we made 
sure to include detection methods that relied upon silent polymorphic sites that 
avoid such selection pressures entirely. We also used linear and logistic regression 
in addition to other methods in order to further test the reliability of our results, 
particularly for programs that had great sensitivity along with higher number of 
false positives. In the materials and methods section we describe the 
characterization of the different programs. Here discuss the results obtained, 
including parameter estimations, p-values, or graphical representations, for the 
clinical data sets. 
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TEM 
SHV 
DnaSP 
R = 44.4 
R 
=10000 
LDhat 
R = 22 
R = 100 
Max Chi 
Squared 
124 recombined 
pairs 
121 recombined 
pairs 
Sawyer's 
Runs Test 
P = 0.04 
P = 0.03 
PHI Test 
P=0.15 
P = 0.07 
Filter 
P = 
0.02 
N/A 
Table 1. Summarizing the results from recombination detection algorithms that 
produced a numberical output. 
Fig. 1: Reticulate Output (Graphically Represented) for TEM and SHV 
Respectively. The black cells are polymorphic sites that cannot be explained if the 
evolution involved mutations only without any recombination. 
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F^. 2: PhylPro Results Showing Linkage Disequilibrium for TEM Indicating 
Frequent Recombination 
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Fig. 3: PhylPro Results Showing Linkage Equilibrium at Zero for SHV Indicating 
Free Recombination 
The algorithms provided results in various different formats. DnaSP, being 
population genetics based algorithm, provides estimate of various population 
parameters based on the sequence data. The program provides two recombination 
parameters R and Rm with values ranging between 0 and 10,000, with R being an 
estimated recombination rate and Rm other being the minimum rate of 
recombination that would be required to generate the population characteristics. In 
addition the program provides the mutation rates (0), and this allows us to obtain 
a recombination to mutation ratio. If recombination is present one should expect 
to obtain a non-zero rate for recombination with this algorithm, and the higher the 
estimated recombination rate the more certain the presence of recombination. For 
TEM we obtained R = 44.4, Rm = 14, and 0 = 8, and for SHV we obtained R = 
10,000, the maximum rate available by the program, Rm = 11, and 0 = 7 . LDhat, 
another population genetics based algorithm, has three recombination rate 
estimates the first two estimating R and Rm as described above and the third being 
the moments method calculation of recombination rate, as well as the Watterson's 
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definition of mutation rate. For TEM we obtained R = 22, Rm = 16, R(moments 
method) = 36, and 0(Watterson) = 22. For SriV R = 100, Rm = 10, R(moments 
method) = 1738, and ©(Watterson) = 16. Once again, if recombination is present 
one should expect to obtain a non-zero rate for recombination with this algorithm, 
and the higher the estimated recombination rate the more certain the presence of 
recombination. The program itself also does a randomization test of data by 
shuffling segments of the sequences as additional measure of reliability by 
comparing various parameter values before and after randomization to examine 
the likelihood of data set characteristics happening by coincidence. The 
randomization results showed: 
1. A reduction in LKmax from 178590 to 0.411 
2. A reduction of G4 from 38855 to 0.3720 
3. An increase in Corr. (r2, d) from 0.01381 to 0.767 
4. An increase in Corr. (D', d) from 0.00563 to 0.4050 
As it can be seen, there are very significant changes to the estimates of every 
parameter once the sequences are recreated with their segments randomized, 
indicating that the sequence characteristics of our clinical data sets are not 
coincidental. Furthermore linkage equilibrium (Corr. ~ 0) has been indicative of 
free recombination in the literature [15]. 
The Reticulate algorithm has a graphically displayed matrix as shown in Fig. 1, with 
the black cells indicating that there are polymorphic sites that cannot be explained 
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by maximal parsimony trees that only accommodate mutation and no 
recombination. The higher the portion of incompatible cells, the more significant 
presence of recombination is within the population The Max Chi Squared 
algorithm, which is statistical analysis of the clustering of the polymorphic sites, 
produces p-values for recombination between a pair of sequences by shuffling 
different segments of the sequences many time and examining how many of the 
random shuffles show equal or greater recombination signatures than the original 
pair. For TEM we observed that 124 pairs of sequences had recombination present 
with p-values below 0.05, and we observed 121 pair with p-values below 0.05 for 
SHV. Sawyer's Runs test is based gene conversion analysis on a set of sequences, 
and we obtained p-values of 0.04 and 0.03 for recombination presence in TEM 
and SHV respectively. The detection of recombination with statistically significant 
p-values by this method is important for three reasons: first the recombination 
signal was strong enough to overcome the insensitivity of the program (see 
simulation characterization section below), second the method utilizes silent 
mutations and largely avoids any selection pressure, and third if the domain of 
allowable mutations is extended beyond the silent polymorphic sites to all 
polymorphic sites including non-silent ones the p-values go above 0.88 for TEM 
and 0.60 for SHV. The last factor shows that if one looks for recombination based 
on all polymorphic sites, one could miss the recombination signature in the 
evolution of antibiotic resistance due to heavy selection pressures destroying the 
recombination signatures. 
PHI (Pairwise Homoplasy Index), is a site pattern analysis using incompatibility 
scoring that provides p-values for recombination presence. With this algorithm we 
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obtained p-values of 0.15 and 0.07 for recombination presence in TEM and SHV 
respectively. Though the p-values were above 0.05, it was a great surprise for us 
that the recombination signatures were strong enough to give us the lowest p-
values that we ever observed with the PHI test, which lead us to believe that the 
recombination in the clinical datasets were far stronger than those generated 
through our simulations. PhylPro (Phylogenetic Profile Algorithm) produces a 
graphical pairwise sequence comparison that displays the agreement,correlation, of 
patterns of distances using a sliding window analysis also known as linkage 
disequilibrium. It was the analysis in a publication using the program that guided us 
to use near zero correlation of pairwise comparisons, which happened to be the 
case for TEM and SHV shown in Fig. 2 and Fig. 3, as indicating free, or very high, 
recombination in the TEM and SHV genes [15]. 
Linear and logistic regression filters using the R software package for statistical 
analysis were employed to see if we could classify the false positives and true 
positives in different categories and use these findings for our clinical data sets. In 
doing so we tried using the values of the following factors as our input of 
parameters: tetraplasmy (existence of four different/degenerate alleles at the same 
nucleotide site), triplasmy (existence of three different/denerate alleles at the same 
nucleotide site), polymorphic sites, non- informative polymorphic sites, 
informative polymorphic sites, mutations, tetraplasmy divided by triplasmy, 
tetraplasmy divided by polymorphic sites, tetraplasmy divided by non-informative 
sites, tetraplasmy divided by informative sites. The reason behind our original 
selection of factors related to tetraplasmy was that under high selection the active 
sites get selected and fixed within the population almost immediately. After active 
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sites get fixed, the population goes under quasi-neutral evolution. Since 
recombination increases diversity in neutral evolution [16,17] we suspected that 
tetraplasmy should be higher in populations where recombination plays a role. The 
regression resulted in mean values for simulation sequence sets with 
recombination, true positives, and simulation sequence sets without 
recombination, false positives, that were statistically different (p-value: 1.17 x 10~27). 
The classification rejects 98% of false positives while keeping 20% of true positives 
or alternatively rejects 80% of false positives while keeping 40% of true positives. 
TEM was classified as true positive under both versions of the test. SHV only 
carried triplasmic variants; hence this test was not applicable. The logistic and 
weighted logistic regressions produced similar results without significant 
differences. 
It important to note that above mentioned software algorithms were characterized 
using our group's statistical mechanics based simulation software that is capable of 
evolving populations under various parameter values for mutation and 
recombination. The most important finding from the DnaSP characterization was 
that it showed 100% sensitivity with 45 simulated data sets where recombination 
was present. We expected that the false positive detection for this program be high 
due to fact that our simulation and clinical data did not meet the main underlying 
assumptions of the program, which are infinite site approximation, neutral 
evolution, and constant population size. To our surprise DnaSP avoided false 
positive detections except when faced with high selection on active site (not 
general protein stability selection, but rather the selection on binding and activity 
of the enzyme on the substrate). This would make DnaSP a suitable program to 
124 
check for recombination if one is studying datasets that have not undergone strong 
active site fitness selection. One can keep the possibility of recombination to a 
minimum if the results from this test are not positive. Recombination can never be 
ruled out even if it is not detected. Unfortunately, our clinical data has been under 
strong active site fitness selection, hence we needed to rule out false positive 
detection using our regression methods and did so as explained earlier. 
Characterization of LDhat showed that the algorithm has good sensitivity, and has 
multiple outputs that if all confirm each other give a more robust conclusion. 
Unfortunately LDhat also had a false positive detection weakness under strong 
active site fitness selection. Here again the program showed presence of 
recombination. Again, we needed to rule out false positive detection using our 
regression methods and did so as explained earlier. Characterization of the 
Reticulate algorithm found it to be both sensitive but inaccurate. Reticulate 
algorithm generated a graphical matrix output, where the black cells indicate that 
there are polymorphic sites that cannot be explained by maximal parsimony trees 
that only accommodate mutation and no recombination. The higher the portion of 
incompatible cells the higher the rate of recombination. Here the p-value generated 
was a test on random reproducibility of clustering of the black cells observed. 
The Max Chi Squared algorithm was found to be sensitive by the characterization 
nevertheless, it allowed for false positive detection both under strong active site 
fitness selection as well as general selection. Again the program indicates presence 
of recombination. There is a concern about false positive detection with strong 
active site fitness selection that needed addressing using the filter. General 
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selection was ruled out by previous software programs. The software 
characterization of Sawyer's Runs test showed it to be very insensitive, and gave p-
values around 0.5 for simulation generated datasets that employed recombination. 
Consequently, we did not obtain any false positives detections using this algorithm. 
The PHI test algorithm was characterized to be not sensitive. It did not detect 
recombination a single time even when present and the p-values were generally 
around 0.80 and not a single one was below 0.50. It was considered vary positive 
indications that the lowest p-values ever obtained by us using the Sawyer's Runs 
test and PHI test were those of the TEM and SHV. As for the PhylPro algorithm, 
characterization showed some distinguishing characteristics between the false 
positives and the true positives, but due to the non-quantitative nature of the 
program it was hard to have distinct cut off values/characteristics for 
distinguishing between true and false positive values. 
Table 2. Summary of Characterization of Recombination Detection 
Algorithms Using Simulations and as well as the Results Obtained for 
ESBL Clinical Isolates for Presence of Recombination. 
Software 
Sensitivity 
Accuracy 
TEM 
SHV 
DNASP 
Sensitive 
Inaccurate 
Positive 
Positive 
LDhat 
Sensitive 
Inaccurate 
Positive 
Positive 
Reticulate 
Sensitive 
Inaccurate 
Positive 
Positive 
Max Chi 
Squared 
Sensitive 
Inaccurate 
Positive 
Positive 
Sawyers 
Runs Test 
Insensitive 
Accurate 
Positive 
Positive 
PhylPro 
Sensitive 
Inaccurate 
Positive 
Positive 
PHI Test 
Very 
Insensitive 
Accurate 
Negative 
Negative 
Filter 
Insensitive 
Accurate 
Positive 
N/A 
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Discussion and Conclusion 
The theoretical importance of recombination and horizontal gene transfer to the 
emergence of modularity under changing environments and to increased adaptation 
rate in biology have been emphasize [8-12]. Evidence for contribution of 
recombination to mosaic gene structures has been presented [18], which follow as a 
natural expectation of the theoretical work Our findings in this article address the 
situation where the divergent genes cannot be attributed to any one family of 
bacteria, and a chronological family tree cannot be established. 
As presented in the results section, all but one software programs detected 
recombination. If we take into account the extreme insensitivity of the PHI test in 
detecting recombination as established by the simulation characterizations, then 
positive results with every detection program can be presumed. The results were 
further reinforced with linear and logistic regression to make sure the results are 
not due to false positive detection. Considering that these sequences are picked by 
evolutionary selection and obtained from clinical settings, any signature from 
recombination detected in these datasets shows that recombination has already 
played a direct role in the evolution of antibiotic resistance development. Since we 
started this study, the p-values have gone down steadily with addition of new 
sequences in the GenBank and inclusion of non-GenBank sequences that have 
been verbally described in the literature diminishes the significance of 
recombination in the datasets. This gives us extra confidence that with more and 
more data obtained those p-values for the PHI test that are low but not below 0.05 
may reach that level in time, and even without considering simulation 
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characterization of the software packages one will be able to have the same 
conclusions. Another measure that we took to reinforce out findings was to 
remove a progressively larger region of the genes that included the active sites, and 
observe the effect on recombination signature. Under these conditions, we still 
detected recombination for both the TEM and SHV families, though the 
magnitudes of recombination coefficients were smaller to varying degrees in the 
TEM, SHV, and simulation datasets. Below you shall find further evidence of 
recombination in the evolutionary development of antibiotic resistance based on 
the degeneracy of the mutations observed. 
Evolution by point mutation alone leaves some results unexplained. First that 
recombination is known to take place in plasmids on which the resistance genes are 
located. Second in one case there were three strains with a single point mutation 
difference from the original TEM-1 strain each [4,19], and there also existed every 
possible combination of these three mutations in the population in an exhaustive 
manner. The evidence for recombination was so strong that the author proposed 
combination (without using the term recombination) as a strong possibility for 
obtaining the combinatorial variants. We examined the population in order to see 
how many strains could be obtained by simply combining other strains with single 
mutations together. Combining five strains with a single mutation difference from 
TEM-1 each (TEM-2, TEM-12, TEM-17, TEM-19, and TEM-29) gives rise to 11 
new strains that are already in the population (TEM-3, TEM-6, TEM7, TEM-11, 
TEM-15, TEM-16, TEM-18, TEM-26, TEM-44, TEM-129, and TEM-134) 
providing us with a diversity of 17 from the exhaustive 32 possible variants of these 
5 mutations in clinical isolates. With rise of about 30 different varieties of TEM due 
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to mutations in only 8 sites and mutations in 5 sites giving rise to about 15 different 
varieties of SHV p-lactamase genes, recombination seems a more plausible 
explanation by giving us an evolutionary timeline on the order of decades. 
One of the major implications of our results is the increase in diversity of |3-
lactamase resistance in short timeframes, which is already observed in clinical 
settings. Though this complements our prior publications [8-12] as well as those 
from other groups [16], it is not agreed upon by all [20]. Increase in the population 
diversity leads to higher propensity for evolution of resistance in bacteria carrying 
these genes. This implies that despite different mutation combinations having 
varying resistance levels, the overall population can contain most if not all of them 
allowing for many if not all available evolutionary pathways allowing for future 
adaptability. This is of particular importance because it allows the bacteria to adapt to 
local fitness loci without being trapped there and still be adaptable to future 
environmental/antibiotic changes. Recombination can explain results that otherwise 
seem unlikely [21]. For example, a calculation of the 99% probability density of 
evolutionary pathways for TEM-1 to become resistant to Cefotaxime predicted 10 
pathways, yet some of the clinically observed data were not present in those 
pathways. This result suggests the presence of recombination. Recombination can 
explain these inconsistencies by allowing for diversity beyond the fittest strains and 
allowing for combining of the mutations in many different ways. With 
recombination, it is important to notice that the bacteria seem to increase their 
resistance to certain antibiotics to moderate levels without being trapped in local 
minima that can reduce their adaptability in the future. 
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Since we used clinical sequences that have been evolutionary selected in real life 
settings, our findings complement the results from [16]. They had shown for the (3-
lactamase genes in particular that with random mutation the functionality of the new 
strains declines exponentially with accumulation of mutations due to lack of 
conservation of the protein fold. Recombination in |3-lactamase genes, however, not 
only does not have an exponential decline, moreover in curves symmetrically and 
log-parabolicaUy giving rise to "broad diversity with relatively low cost in loss of 
function" [16]. In this article of ours, we showed that organisms are already taking 
advantage of such benefits by using recombination for their evolution even over 
short distances in the fitness landscape. More importantly, in our previous 
publications [8-12] we had shown that the greatest contribution from recombination 
is increasing the evolution rate of a population. Our previous findings along with the 
new observations in clinical datasets lead us to conclude that recombination (due to 
its speeding up of evolution in populations by fast utilization of resources/diversity 
already available to the population, conservative nature in preserving function under 
the right conditions, creating broad diversity, and exchanging genetic information 
among different organisms) is a significant contributor to evolution; let it be bringing 
mutations together, mechanistic contributions to generate mutations, gene 
rearrangements and amplification, or horizontal gene transfer in mosaic gene 
segments within and between species. 
Materials and Methods 
Statistical mechanics based simulation software developed by our group: The 
program was a modification of [9,22] that we modified to correspond to our 
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simulation needs in this project. We set the sequence length to 1000 amino acids. 
We set the ratio of recombination to mutation to range from 0 to 10, with half the 
results at a ratio of 0 and the rest equally performed at 1,5, and 10. We set the 
strength of selection based active site, which measures the degree of selection on 
the active site residues, to have a weight of 1 to 50, with a ratio of 5 chosen for 
final simulations. We used two population sizes of 100 and 300, with most 
simulations performed at a size of 100. These parameters mimic that of the 
clinically observed TEM and SHV [22]. The simulations typically went through 
100,000 rounds of replication and selection to generate the data sets. For each 
parameter value, we performed 45 simulations. The simulations were used to 
characterize various software programs employed under various evolutionary 
conditions. We used a generalized NK model to simulate the evolution of the 
protein enzyme. The active site fitness constant of enzyme and target is of the 
following form: exp(a - b<U>), where a and b are constants, and we define U 
(the measure of fitness of interaction where the lower the value of U is the fitter 
the enzyme has become) for the enzyme by 
M M P 
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"' jM(N-K + l) P a' J J+l J+K~l 
U^a.ia^NP 
Ykre the number of enzyme secondary structures is M = 100. The number of 
enzyme amino acids in the active site is P = 5. The number of amino acids in a 
single secondary structure sub-domain is N = 10, and range of local interactions is 
K = 4 amino acids. There are L =5 different sub-domains in a secondary structure 
(helices, strands, loops, turns and others) represented by the subscript a;. The 
number of interactions between secondary structures is D = 6. The first 
summation is over all the interactions within a secondary structure. The second 
term represents the inter-secondary structure interactions. The total number of 
interaction that a typical amino acid can have is roughly 12, and [2(k-l)] of them 
are within secondary structure sub-domain and [D(M-1)/N] are in the inter-
secondary structure sub-domain interactions. For sequence length of M x N = 100, 
the simulation is expected to be a semi-quantitative model of a protein domain. 
For our case to be comparable to the clinical sequence length we chose M = 100, 
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making the length M x N = 1000. The third summation represents the active site 
measure of fitness and its fitness is represented by a reduction in this parameter. 
The sites considered for the active site fitness parameter represented the active site 
residues in the TEM and SHV structures. This allows for simulation study of the 
evolution of active site residues under different conditions. Also there is a strong 
correlation between the active site fitness and enzyme virulence in clinical data. 
Initially we generate 5 optimized high fitness sub-domain pools, each made of 300 
variants corresponding to L = 5 types to have biologically relevant fitness levels for 
the structures to choose from. Out of each set of 300 we pick 3, then going on to 
generate 1000 random sequences by different combinations of these segments for 
100 different secondary structure positions in each sequence. From this initial 
population, the top 20% is selected based on our fitness formulation. The next 
step is to repopulate back to the original count, and allow for mutation and 
recombination (with parameters set for any specific scenario) among the new 
generation. The selection and repopulation representing one generation cycle is 
repeated for a selected number of generations (we used 30 as well as 100). One 
might find further details in Dr. Sun's paper and relevant references [22]. Then the 
sequences are used to characterize the software programs that were chosen to 
analyze our clinical sequences. 
The simulations are appropriate for such characterizations due to following 
reasons: 
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1. The statistical mechanics GNK model used in the simulation is 
uncorrelated to the detection algorithms that are used in the software 
programs. 
2. The semi-quantitative nature of the simulations makes the sequences 
mimic protein structures closely. 
3. The mutation and recombination parameters are adjustable for 
verification of the software programs responses under different 
condition. 
We used the simulations algorithm described above to generate sequences by point 
mutation, recombination and selection to characterize the detection algorithms 
employed, and better understand and interpret the results obtained from them. To 
detect recombination in populations of interest, we used the following seven 
programs: DnaSP, Reticulate, LDhat, START, Phylpro, and SplitsTree. Here we 
describe the methodology, assumptions, and claims of the tests preformed by these 
programs. 
DnaSP: 
DnaSP, DNA sequence polymorphisms, is a population genetics based program 
that has algorithms allowing for several measurements within and between 
populations [23,24]. The recombination test for the program is based on an 
algorithm that generates rate of recombination (R), as well as the lower bound 
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estimate for the recombination rate (Rm) [25,26]. In addition the D, D', two other 
estimates for recombination rate (R and R2) are calculated under the linkage 
disequilibrium algorithm of the software [24]. The algorithm assumes an infinite 
site model, constant population size, random mating and no population structure. 
The algorithm disregards sites with recurrent mutations and had no selection 
component. 
LDhat: 
The LDhat program is based on population genetics methods [27]. It implements 
the approximate likelihood algorithm with some modifications [27]. It is adapted to 
a finite-site model, can use both haplotype as well as genotype data, estimates 
variable recombination rates [28], gives the option of including tri/tetra-plasmic 
sites, and tolerates an arbitrary amount of missing data. This software also 
produces measurements of linkage disequilibrium. 
Reticulate: 
Reticulate uses a sites patterns analysis approach [29]. Reticulate evolution refers to 
inter-dependent evolution among different lineages, which can come from 
recombination or inter-speciation. The later is not relevant to the populations of 
our study. The program generates a matrix of pairwise compatibilities and provides 
a statistical analysis of the clustering obtained from compatible sites. The algorithm 
computes a Neighbor Similarity Score, does not have any underlying assumptions, 
and can do a sliding window analysis to locate recombination hot spots. 
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START: 
START, Sequence Type Analysis and Recombination Tests, performs Max Chi 
Squared test for recombination as well as Sawyer's Runs test [30].; both of which 
are based on pairwise sequence comparisons [30-33]. The Max Chi Squared test is 
statistical analysis of clustering of polymorphic sites for a pair of sequences. The 
Sawyer's Runs Test is based on the gene conversion analysis in a set of sequences 
explained in [32]. This test relies on the silent mutation sites for its analysis. It 
looks to determine if there are more consecutive identical silent polymorphic sites 
in different regions than that predicted by general probabilities. Both of these 
programs do not have any underlying assumptions; furthermore, the Sawyer's Runs 
Test is based on silent mutation sites that are entirely unaffected by selection 
pressures. 
SplitsTree: 
SplitsTree is a phylogenic network analysis program [34,35]. This program was 
used primarily to perform the PHI test, which is Pairwise Homoplasy Index [36]. 
The algorithm is a site pattern analysis using incompatibility scoring. This is a 
general test with no underlying assumptions, which claims to discern between 
recurrent mutation and recombination. It also claims that it is the best performing 
algorithm with regard to other parameters as well. 
PhylPro: 
PhylPro, Phylogenic Profile Algorithm, is a graphical pairwise sequence 
comparison program [37]. It uses a sliding window algorithm to analyze the 
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agreement of patterns of distances in particular regions. Even though graphical 
representations are able to give cues for patterns that are hard to quantify, this lack 
of quantification can lead to difficulty of interpretation of the results. Nevertheless, 
the graph is based on pairwise correlations and recombination destroys the 
correlation signal. Hence the evidence for recombination becomes more definitive 
as the square or absolute value of results nears zero. The paper [37] does not 
mention any underlying assumptions for its algorithm. 
137 
Chapter V 
ENTROPY CALCUCLATIONS FOR MUTATIONS IN CAPSID PROTEINS 
OF HUMAN RHINOVIRUSES: AN ATTEMPT TO LOCALIZE EPITOPE 
RESIDUES 
Introduction 
Rhinoviruses are the most diverse member of die Picornaviruse family [1]. 
Picornaviruses, though a small RNA virus without an envelope, are die source of 
most viral infections in die world [2]. Rhinoviruses diemselves are die predominant 
padiogen in bringing about acute respiratory tract illnesses [3]. They can infect bodi 
the upper human respiratory tract, causing die common cold, and occasionally in the 
lower tract regions [4,5]. Due to our familiarity with die diseases that is caused by 
diis virus, we have come to consider it innocuous. The common cold is die 
dominant cause of morbidity in younger children [6], main disease diat leads to 
prescription of antibiotics in general, diough erroneously [2], and most common 
pathogen associated widi initiation and exacerbation of asthma and expiratory 
wheezing [3,7,8]. Hence, our misconception of diis familiar disease being innocuous 
and caused by a single group of slightly varying strains has lead to comparative 
understudying of this virus for the passed five decades, placing a heavy burden on 
global healdicare resources in tens of billions of dollars each year [9]. There has been 
recent evidence [10] to suggest that the HRV modulates die immune system in order 
to suppress and disregulate it. Summarizing die problem at hand, the statement from 
[11] has become a common quote: "What had appeared to be a single disease 
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capable of a single solution turns out to be something of unimagined complexity 
for which there is no straightforward answer.". 
Though individual strains of HRV are relatively conserved and can confer protective 
immunity after the initial infection, due to the broad diversity other strains can infect 
the individual giving rise to the symptoms all over again. One of the basic 
understandings that has been missing about HRV is proper definition of the epitope 
regions for various strains. In this work we try to gain a better understanding of 
which residues may give rise to the epitopes recognized by the immune system in 
HRV. Specifically, we characterize the mutation is sequence data from clinical studies 
in humans that was provided by our collaborators in Maryland using HRV39. 
Results 
We found the mutations not to be randomly distributed and having an effective 
spread of 0.47 among the mutant sites, and generally observed the mutations to 
occur at about 50 sites out of approximately 880 residues in the HRV capsid 
proteins. Furthermore we found three mutation hotspots at the 345th to 350th, 366th 
to 369th, and 806th to 808th amino acid positions in the capsid protein sequence. The 
criteria for considering the mutations allowable were: the mutation must be seen in 
more than one read to make sure that it is not a byproduct of a specific probe, the 
mutation must be more than 2% of the population in at least one single read. 
The table below summarizes the mutations observed mutations in progeny virus 
sequences obtained from the clinical studies. The sequence reads were aligned with 
HRV capsid protein reference and the mutants were tabulated, (reference sequence: 
MGAQVSRQNVGTHSTQNSVSGGSSLNYFNINYFKDAASSGASKLEFSQDP 
SKFTDPVKDVLEKGIPTLQSPTVEACGYSDRIIQITRGDSTITSQDVANAVV 
139 
GYGVWPHYLTADDASAIDKPTQPDTSSNRFYTLESKVWKRDSKGWWWK 
IJ>DALKDMGIFGE^MYYHFLGRSGYTVHVQCNASKFHQGTLLIAMVPE 
HQIJ^ANYGKVTAGYNYTHPGEAGRDVGQQRTNNEKQPSDDNWLNF 
DGTLLGNLUFPHQHNIJISNNSATIIWYVNAWMDSMLRHNNWSLUIPV 
SPI^ ADTSATAIVPITVSISPMFSEFSGARARPAAATQGLPVYMIPGSGQFLT 
TDDLQSPSAl^WYHPlXEIHPGQVRNLIEMGQVDTMIPINKrNERIGNV 
NMYTVSLISQTNTAEQIFAIKVDIASQPLSS'IIJGEIASYYTHWTGSLRFSFM 
FCGTANTIliCLLIJVYTPPGIDKPTrFaCQAMLG'IHIVWDVGLQSTVSLVVP 
WVSASHFRYTIHyiYSMAGYITO^^ 
DFCLRA4ARDTDMIWQNWITQNPVE>raDEVIJ^EVLVVPNIRESHPTr5N 
AATALDAAETGHTSSIQPEDTIETRYVQTSHTRDEMSVESFLGRSGaHIST 
ITMCKENYNEHNFVD\!^ITLQEMAQVRRKFEMFTYVRFDSEITLVPaA 
GRGEDIGHIVMQYMYVPPGAPVPKKRDDTrWQSGTNASVFWQHGQPY 
PRFSIJ)FL I^ASAYYMFYDGYDGDKSSSRYGVSVT^©MGTLCIKIVTNQQK 
HLVEVTmVYHKAKFIVKAWCPRAPRAWYTHSNVTNYKVRDGEPTLnK 
PRENLTTAGPSDMYVFIVGNLIYRNLFILFNSE). 
Loci 
46 
47 
111 
139 
155 
162 
163 
185 
216 
232 
Freq. 
2 
1 
Loci 
233 
237 
305 
345 
346 
347 
348 
350 
358 
366 
Freq. 
2 
1 
1 
1 
1 
4 
3 
. 3 
1 
1 
Loci 
367 
368 
369 
377 
410 
411 
429 
446 
455 
471 
Freq. 
4 
3 
2 
1 
Loci 
487 
512 
527 
528 
574 
577 
582 
596 
617 
634 
Freq. 
1 
1 
1 
4 
1 
3 
1 
11 
1 
1 
Loci 
660 
667 
748 
806 
808 
817 
824 
825 
833 
837 
Freq. 
1 
1 
1 
4 
4 
1 
3 
1 
1 
2 
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Fraquenoy of Mutation at a Partieualr Site in Various Reads 
O Mutation Frequence 
Caps Id Protein Sequence Residue 
Discussion and Conclusion 
We considered it important to show that the mutation in HRV progeny are focused 
on certain residues. Since die studies were performed in human subjects with the 
selection pressures of the immune system, we presume that the mutations occur in 
the immunogenic regions i.e. the epitopes. Since epitopes are generally found to be 
the surface residues of a continuous stretch of die protein sequence, these results 
shall help determine the epitope loci of HRV14 in the capsid protein. 
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Chapter VI 
SUMMARY AND CONCLUSION 
In this thesis, pathogens' co-evolution with the immune system was studied using 
several specific examples. Though these pathogens are very diverse and widely 
varying, as is the case in biology generally, we have come to understand some 
fundamental notions in the evolution of these pathogens in tandem with human 
immune system evolution. The first observed principle was that models from 
statistical mechanics such as generalized NK models, random energy models, and 
maximum entropy models can be utilized to answer biological questions that at some 
point were considered intractable. The fact that the of laws statistical mechanics are 
the underlying principle governing thermodynamics and its uses in engineering, 
information theory, and biology is fascinating a gives us a common link, allowing us 
to utilize developments in one field to solve problems in another. The second 
observed principle was the observed non-randomness in evolution of both 
pathogens and the immune system. 
If true, correlations in the structure of biology and the dynamics of evolution can be 
a dilemma and a solution at the same time. There seems to be historical and co-
evolutionary imprinting on both the pathogen and the immune system which can be 
partially captured using statistical mechanics models. One of the implication of such 
imprinting would be pathogens being smart due to a built in evolutionary database 
created through long term interaction with the environment. It also would make the 
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immune system less diverse than theoretically postulated. However, the most 
important implication of it is with regard to our active interference in the pathogen-
immune interactions. If our goal stays the one that we have had until now, using all 
available tools to enhance our longevity even for the briefest periods as individuals, 
we can force pathogens to evolve faster. If pathogens evolve faster than our immune 
system or therapeutic strategies, we are trading the longevity of individuals now with 
survival of other individuals in the future. So we should take advantage of the 
observation that pathogen evolution does not access the entirety of the fitness 
landscape in a manner that would not lead to faster rates of pathogen evolution or 
better yet it would retard its pace. Also, since the evolution seems non-random due 
to preexisting correlations in structure and dynamics, we should characterize and 
utilize the evolutionary traits of pathogens in order to have a better understanding of 
what we shall confront in the future. 
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